Randomized controlled trials for fluoxetine in chronic pain management.
\r\n\tThe book will also discuss various linkers and protecting groups used in synthesis. Coming to the application part of peptides in brain drug delivery it is proposed to include nanotechnology. The efficiency of many drugs is restricted to their potential to reach the site of therapeutic action. In recent years, the use of nanotechnology has been considered as a valuable strategy to achieve drug delivery to the brain by using nanoparticles to transport drug molecules across BBB. It is suggested to include a detailed description on Peptides as ligands of nanoparticles in brain drug delivery in the book. The proposed Peptide Synthesis book supplies a broad, yet straightforward approach that appeals to those with limited knowledge of organic chemistry or chemists from other fields as well as in-depth coverage that can be appreciated by experienced peptidologists.
',isbn:null,printIsbn:null,doi:null,price:0,slug:null,numberOfPages:0,isOpenForSubmission:!1,hash:"de9fa48c5248dbfb581825b8c74f5623",bookSignature:"Dr. Jaya T. Varkey",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/8622.jpg",keywords:"Peptide Synthesis, Solid Phase Synthesis, Polymer Support, Swelling and Salvation, Hydrophilic, Hydrophobic",numberOfDownloads:null,numberOfWosCitations:0,numberOfCrossrefCitations:0,numberOfDimensionsCitations:null,numberOfTotalCitations:null,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"November 5th 2018",dateEndSecondStepPublish:"November 26th 2018",dateEndThirdStepPublish:"January 25th 2019",dateEndFourthStepPublish:"April 15th 2019",dateEndFifthStepPublish:"June 14th 2019",remainingDaysToSecondStep:"3 months",secondStepPassed:!0,currentStepOfPublishingProcess:4,editedByType:null,editors:[{id:"246502",title:"Dr.",name:"Jaya",middleName:null,surname:"T. Varkey",slug:"jaya-t.-varkey",fullName:"Jaya T. Varkey",profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:"St. Teresa’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"0",totalChapterViews:"0",totalEditedBooks:"0",institution:null}],coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"8",title:"Chemistry",slug:"chemistry"}],chapters:null,productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"278926",firstName:"Ivana",lastName:"Barac",middleName:null,title:"Ms.",imageUrl:"https://mts.intechopen.com/storage/users/278926/images/8058_n.jpg",email:"ivana.b@intechopen.com",biography:"As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"7303",title:"Formaldehyde",subtitle:null,isOpenForSubmission:!1,hash:"74a54fee24b3957a531fd6a415bd0383",slug:null,bookSignature:"Dr. Hussein Abdelhay Essayed Kaoud",coverURL:"https://cdn.intechopen.com/books/images_new/7303.jpg",editedByType:null,editors:[{id:"265070",title:"Dr.",name:"Hussein Abdelhay",surname:"Essayed Kaoud",slug:"hussein-abdelhay-essayed-kaoud",fullName:"Hussein Abdelhay Essayed Kaoud"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7344",title:"Rhodium",subtitle:null,isOpenForSubmission:!1,hash:"2f20ad76fa8d51c4a063f1f31e2f4973",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/7344.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7735",title:"Surfactants and Detergents",subtitle:null,isOpenForSubmission:!1,hash:"bca8bb6e94e26599889ff5e1190b0ed7",slug:null,bookSignature:"Dr. Ashim Kumar Dutta",coverURL:"https://cdn.intechopen.com/books/images_new/7735.jpg",editedByType:null,editors:[{id:"277477",title:"Dr.",name:"Ashim",surname:"Dutta",slug:"ashim-dutta",fullName:"Ashim Dutta"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7743",title:"Redox",subtitle:null,isOpenForSubmission:!0,hash:"5f364cc129c1b9710ff56e0fad989bd9",slug:null,bookSignature:"Prof. Rozina Khattak",coverURL:"https://cdn.intechopen.com/books/images_new/7743.jpg",editedByType:null,editors:[{id:"207213",title:"Prof.",name:"Rozina",surname:"Khattak",slug:"rozina-khattak",fullName:"Rozina Khattak"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8540",title:"Dehydration of Alcohols",subtitle:null,isOpenForSubmission:!0,hash:"55b9333e1c424d08555503e38b1c6279",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/8540.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8609",title:"Dyes in Industry",subtitle:null,isOpenForSubmission:!1,hash:"b07f3cc3752f4360baf785cd31dad4ae",slug:null,bookSignature:"Prof. Nasser S Awwad and Dr. Hamed Majdooa Algarni",coverURL:"https://cdn.intechopen.com/books/images_new/8609.jpg",editedByType:null,editors:[{id:"145209",title:"Prof.",name:"Nasser",surname:"Awwad",slug:"nasser-awwad",fullName:"Nasser Awwad"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8758",title:"Polychlorinated Dioxins in the Environment",subtitle:null,isOpenForSubmission:!0,hash:"3a9288a0550072f7bc6751a6d706ef46",slug:null,bookSignature:"Dr. Radim Vacha and Prof. Ivan Holoubek",coverURL:"https://cdn.intechopen.com/books/images_new/8758.jpg",editedByType:null,editors:[{id:"208111",title:"Dr.",name:"Radim",surname:"Vacha",slug:"radim-vacha",fullName:"Radim Vacha"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8852",title:"Benzimidazole and its Derivatives",subtitle:null,isOpenForSubmission:!1,hash:"e95984a2b87df5a7ca051cb3345d5e7a",slug:null,bookSignature:"Ph.D. Maria Marinescu",coverURL:"https://cdn.intechopen.com/books/images_new/8852.jpg",editedByType:null,editors:[{id:"250975",title:"Ph.D.",name:"Maria",surname:"Marinescu",slug:"maria-marinescu",fullName:"Maria Marinescu"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8889",title:"Innovative Solvents",subtitle:null,isOpenForSubmission:!0,hash:"75c7231408f17b5af0ff2952627dd5fa",slug:null,bookSignature:"Dr. Daniel Glossman-Mitnik",coverURL:"https://cdn.intechopen.com/books/images_new/8889.jpg",editedByType:null,editors:[{id:"32498",title:"Dr.",name:"Daniel",surname:"Glossman-Mitnik",slug:"daniel-glossman-mitnik",fullName:"Daniel Glossman-Mitnik"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6832",title:"Ruthenium",subtitle:null,isOpenForSubmission:!1,hash:"d1658ac0461b6a400613365f5bfb2124",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/6832.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"37275",title:"Study of Mycobacterium Tuberculosis by Molecular Methods in Northeast Mexico",doi:"10.5772/37412",slug:"study-of-mycobacterium-tuberculosis-by-molecular-methods-in-northeast-mexico",body:null,keywords:null,chapterPDFUrl:"https://cdn.intechopen.com/pdfs/37275.pdf",chapterXML:null,downloadPdfUrl:"/chapter/pdf-download/37275",previewPdfUrl:"/chapter/pdf-preview/37275",totalDownloads:1580,totalViews:62,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,dateSubmitted:"June 2nd 2011",dateReviewed:"November 30th 2011",datePrePublished:null,datePublished:"May 30th 2012",readingETA:"0",abstract:null,reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/37275",risUrl:"/chapter/ris/37275",book:{slug:"polymerase-chain-reaction"},signatures:"H. W. Araujo-Torres, J. A. Narvaez-Zapata, M. G. Castillo-Alvarez, MS. Puga-Hernandez, J. Flores-Gracia and M. A. Reyes-Lopez",authors:[{id:"112638",title:"Dr.",name:"Miguel Ángel",middleName:null,surname:"Reyes-López",fullName:"Miguel Ángel Reyes-López",slug:"miguel-angel-reyes-lopez",email:"mreyesl@ipn.mx",position:"Scientist",institution:{name:"Instituto Politécnico Nacional",institutionURL:"http://www.ipn.edu.mx/",country:{name:"Mexico"}}},{id:"112645",title:"Dr.",name:"José Alberto",middleName:null,surname:"Narváez-Zapata",fullName:"José Alberto Narváez-Zapata",slug:"jose-alberto-narvaez-zapata",email:"janz_21_70@hotmail.com",position:null,institution:null},{id:"117929",title:"MSc.",name:"Hernán",middleName:null,surname:"Araujo-Torres",fullName:"Hernán Araujo-Torres",slug:"hernan-araujo-torres",email:"hernanwat@hotmail.com",position:null,institution:null},{id:"117930",title:"MSc.",name:"Guadalupe",middleName:null,surname:"Castillo-Alvarez",fullName:"Guadalupe Castillo-Alvarez",slug:"guadalupe-castillo-alvarez",email:"inggpecastillo@hotmail.com",position:null,institution:null},{id:"117932",title:"Dr.",name:"Juan",middleName:null,surname:"Flores-García",fullName:"Juan Flores-García",slug:"juan-flores-garcia",email:"jfloresgracia@yahoo.com.mx",position:null,institution:null},{id:"144034",title:"Prof.",name:"María Del Socorro",middleName:null,surname:"Puga-Hernández",fullName:"María Del Socorro Puga-Hernández",slug:"maria-del-socorro-puga-hernandez",email:"coquisnice@hotmail.com",position:null,institution:null}],sections:null,chapterReferences:null,footnotes:null,contributors:null,corrections:null},book:{id:"1769",title:"Polymerase Chain Reaction",subtitle:null,fullTitle:"Polymerase Chain Reaction",slug:"polymerase-chain-reaction",publishedDate:"May 30th 2012",bookSignature:"Patricia Hernandez-Rodriguez and Arlen Patricia Ramirez Gomez",coverURL:"https://cdn.intechopen.com/books/images_new/1769.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"111314",title:"Dr.",name:"Patricia",middleName:null,surname:"Hernandez-Rodriguez",slug:"patricia-hernandez-rodriguez",fullName:"Patricia Hernandez-Rodriguez"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"37258",title:"Application of PCR in Diagnosis of Peste des Petits Ruminants Virus (PPRV)",slug:"application-of-pcr-in-diagnosis-of-peste-des-petits-ruminants-virus-pprv-",totalDownloads:2287,totalCrossrefCites:0,signatures:"Muhammad Abubakar, Farida Mehmood, Aeman Jeelani and Muhammad Javed Arshed",authors:[{id:"112070",title:"Dr.",name:"Muhammad",middleName:null,surname:"Abubakar",fullName:"Muhammad Abubakar",slug:"muhammad-abubakar"},{id:"117674",title:"Dr.",name:"Muhammad",middleName:null,surname:"Javed Arshed",fullName:"Muhammad Javed Arshed",slug:"muhammad-javed-arshed"},{id:"150073",title:"Ms.",name:"Farida",middleName:null,surname:"Mehmood",fullName:"Farida Mehmood",slug:"farida-mehmood"},{id:"150074",title:"Ms.",name:"Aeman",middleName:null,surname:"Jeelani",fullName:"Aeman Jeelani",slug:"aeman-jeelani"}]},{id:"37259",title:"Application of PCR-Based Methods to Dairy Products and to Non-Dairy Probiotic Products",slug:"application-of-pcr-based-methods-to-dairy-products-and-to-non-dairy-probiotic-products",totalDownloads:2771,totalCrossrefCites:2,signatures:"Christophe Monnet and Bojana Bogovic Matijasic",authors:[{id:"110344",title:"Dr.",name:"Bojana",middleName:null,surname:"Bogovič Matijašic",fullName:"Bojana Bogovič Matijašic",slug:"bojana-bogovic-matijasic"},{id:"119861",title:"Dr.",name:"Christophe",middleName:null,surname:"Monnet",fullName:"Christophe Monnet",slug:"christophe-monnet"}]},{id:"37260",title:"Role of Polymerase Chain Reaction in Forensic Entomology",slug:"role-of-polymerase-chain-reaction-in-forensic-entomology",totalDownloads:2148,totalCrossrefCites:0,signatures:"Tock Hing Chua and Y. V. Chong",authors:[{id:"110588",title:"Prof.",name:"Tock Hing",middleName:null,surname:"Chua",fullName:"Tock Hing Chua",slug:"tock-hing-chua"}]},{id:"37261",title:"PCR for Screening Potential Probiotic Lactobacilli for Piglets",slug:"pcr-for-screening-potential-probiotic-lactobacilli-for-piglets",totalDownloads:2118,totalCrossrefCites:0,signatures:"Maurilia Rojas-Contreras, Maria Esther Macias-Rodriguez and Jose Alfredo Guevara Franco",authors:[{id:"114049",title:"PhD.",name:"Maurilia",middleName:"Rojas",surname:"Contreras",fullName:"Maurilia Contreras",slug:"maurilia-contreras"}]},{id:"37262",title:"Polymerase Chain Reaction for Phytoplasmas Detection",slug:"polymerase-chain-reaction-for-phytoplasmas-detection",totalDownloads:3962,totalCrossrefCites:2,signatures:"Duska Delic",authors:[{id:"114083",title:"Dr.",name:"Duska",middleName:null,surname:"Delic",fullName:"Duska Delic",slug:"duska-delic"}]},{id:"37263",title:"Molecular Diagnostics of Mycoplasmas: Perspectives from the Microbiology Standpoint",slug:"molecular-diagnostics-of-mycoplasmas-perspectives-from-the-microbiology-standpoint",totalDownloads:2835,totalCrossrefCites:0,signatures:"Saul Flores-Medina, Diana Mercedes Soriano-Becerril and Francisco Javier Diaz-Garcia",authors:[{id:"117614",title:"Dr.",name:"Saul",middleName:null,surname:"Flores-Medina",fullName:"Saul Flores-Medina",slug:"saul-flores-medina"},{id:"139470",title:"Dr.",name:"Francisco",middleName:"Javier",surname:"Díaz-García",fullName:"Francisco Díaz-García",slug:"francisco-diaz-garcia"},{id:"139472",title:"MSc.",name:"Diana Mercedes",middleName:null,surname:"Soriano-Becerril",fullName:"Diana Mercedes Soriano-Becerril",slug:"diana-mercedes-soriano-becerril"}]},{id:"37264",title:"BRAF V600E Mutation Detection Using High Resolution Probe Melting Analysis",slug:"braf-v600e-mutation-detection-using-high-resolution-probe-melting-analysis",totalDownloads:23162,totalCrossrefCites:0,signatures:"Jennifer E. Hardingham, Ann Chua, Joseph W. Wrin, Aravind Shivasami, Irene Kanter, Niall C. Tebbutt and Timothy J. Price",authors:[{id:"111314",title:"Dr.",name:"Patricia",middleName:null,surname:"Hernandez-Rodriguez",fullName:"Patricia Hernandez-Rodriguez",slug:"patricia-hernandez-rodriguez"},{id:"111320",title:"Dr.",name:"Arlen",middleName:null,surname:"Gomez Ramirez",fullName:"Arlen Gomez Ramirez",slug:"arlen-gomez-ramirez"}]},{id:"37265",title:"Polymerase Chain Reaction: Types, Utilities and Limitations",slug:"polymerase-chain-reaction-types-utilities-and-limitations",totalDownloads:2011,totalCrossrefCites:1,signatures:"Patricia Hernandez-Rodriguez and Arlen Gomez Ramirez",authors:[{id:"112814",title:"Dr.",name:"Jennifer",middleName:null,surname:"Hardingham",fullName:"Jennifer Hardingham",slug:"jennifer-hardingham"}]},{id:"37267",title:"The Application of PCR-Based Methods in Food Control Agencies – A Review",slug:"the-application-of-pcr-based-methods-in-food-control-agencies-a-review",totalDownloads:5666,totalCrossrefCites:1,signatures:"Azuka Iwobi, Ingrid Huber and Ulrich Busch",authors:[{id:"118570",title:"Dr.",name:"Azuka",middleName:null,surname:"Iwobi",fullName:"Azuka Iwobi",slug:"azuka-iwobi"},{id:"120093",title:"Dr.",name:"Ingrid",middleName:null,surname:"Huber",fullName:"Ingrid Huber",slug:"ingrid-huber"},{id:"120094",title:"Dr.",name:"Ulrich",middleName:null,surname:"Busch",fullName:"Ulrich Busch",slug:"ulrich-busch"}]},{id:"37268",title:"PCR in Food Analysis",slug:"pcr-in-food-analysis",totalDownloads:5981,totalCrossrefCites:1,signatures:"Anja Klancnik, Minka Kovac, Natasa Toplak, Sasa Piskernik and Barbara Jersek",authors:[{id:"117947",title:"Dr.",name:"Barbara",middleName:null,surname:"Jeršek",fullName:"Barbara Jeršek",slug:"barbara-jersek"},{id:"138650",title:"Dr.",name:"Minka",middleName:null,surname:"Kovač",fullName:"Minka Kovač",slug:"minka-kovac"},{id:"138651",title:"Dr.",name:"Nataša",middleName:null,surname:"Toplak",fullName:"Nataša Toplak",slug:"natasa-toplak"},{id:"138652",title:"Ms.",name:"Saša",middleName:null,surname:"Piskernik",fullName:"Saša Piskernik",slug:"sasa-piskernik"},{id:"138653",title:"Dr.",name:"Anja",middleName:null,surname:"Klančnik",fullName:"Anja Klančnik",slug:"anja-klancnik"}]},{id:"37269",title:"PCR in Disease Diagnosis of WND",slug:"pcr-in-disease-diagnosis-of-wnd",totalDownloads:1487,totalCrossrefCites:0,signatures:"Asifa Majeed, Abdul Khaliq Naveed, Natasha Rehman and Suhail Razak",authors:[{id:"118945",title:"Dr.",name:"Asifa",middleName:null,surname:"Majeed",fullName:"Asifa Majeed",slug:"asifa-majeed"}]},{id:"37270",title:"Real-Time PCR for Gene Expression Analysis",slug:"real-time-pcr-for-gene-expression-analysis",totalDownloads:4655,totalCrossrefCites:0,signatures:"Akin Yilmaz, Hacer Ilke Onen, Ebru Alp and Sevda Menevse",authors:[{id:"66797",title:"Dr.",name:"Ebru",middleName:null,surname:"Alp",fullName:"Ebru Alp",slug:"ebru-alp"},{id:"112381",title:"Prof.",name:"Sevda",middleName:null,surname:"Menevse",fullName:"Sevda Menevse",slug:"sevda-menevse"},{id:"118059",title:"Dr.",name:"Akin",middleName:null,surname:"Yilmaz",fullName:"Akin Yilmaz",slug:"akin-yilmaz"},{id:"118060",title:"Dr.",name:"Ilke",middleName:null,surname:"Onen",fullName:"Ilke Onen",slug:"ilke-onen"}]},{id:"37271",title:"Recent Advances and Applications of Transgenic Animal Technology",slug:"recent-advances-and-applications-of-transgenic-animal-technology",totalDownloads:14699,totalCrossrefCites:0,signatures:"Xiangyang Miao",authors:[{id:"115311",title:"Prof.",name:"Xiangyang",middleName:null,surname:"Miao",fullName:"Xiangyang Miao",slug:"xiangyang-miao"}]},{id:"37272",title:"Measuring of DNA Damage by Quantitative PCR",slug:"measuring-of-dna-damage-by-quantitative-pcr",totalDownloads:2205,totalCrossrefCites:0,signatures:"Ayse Gul Mutlu",authors:[{id:"115828",title:"Dr.",name:"Ayse Gul",middleName:null,surname:"Mutlu",fullName:"Ayse Gul Mutlu",slug:"ayse-gul-mutlu"}]},{id:"37273",title:"Detection of Apple Chlorotic Leaf Spot Virus in Tissues of Pear Using In Situ RT-PCR and Primed In Situ Labeling",slug:"detection-of-apple-chlorotic-leaf-spot-virus-in-tissues-of-pear-using-in-situ-rt-pcr-and-primed-in-s",totalDownloads:1427,totalCrossrefCites:0,signatures:"Na Liu, Jianxin Niu and Ying Zhao",authors:[{id:"118080",title:"Prof.",name:"Jianxin",middleName:null,surname:"Niu",fullName:"Jianxin Niu",slug:"jianxin-niu"},{id:"137472",title:"Dr.",name:"Na",middleName:null,surname:"Liu",fullName:"Na Liu",slug:"na-liu"},{id:"137473",title:"Dr.",name:"Ying",middleName:null,surname:"Zhao",fullName:"Ying Zhao",slug:"ying-zhao"}]},{id:"37274",title:"Application of PCR Technologies to Humans, Animals, Plants and Pathogens from Central Africa",slug:"application-of-pcr-technologies-to-humans-animals-plants-and-pathogens-from-central-africa",totalDownloads:1478,totalCrossrefCites:0,signatures:"Ouwe Missi Oukem-Boyer Odile, Migot-Nabias Florence, Born Celine, Aubouy Agnes and Nkenfou Celine",authors:[{id:"118147",title:"Dr.",name:"Odile",middleName:null,surname:"Ouwe-Missi-Oukem-Boyer",fullName:"Odile Ouwe-Missi-Oukem-Boyer",slug:"odile-ouwe-missi-oukem-boyer"},{id:"139576",title:"Dr.",name:"Florence",middleName:null,surname:"Migot-Nabias",fullName:"Florence Migot-Nabias",slug:"florence-migot-nabias"},{id:"139577",title:"Dr.",name:"Agnès",middleName:null,surname:"Aubouy",fullName:"Agnès Aubouy",slug:"agnes-aubouy"},{id:"139578",title:"Dr.",name:"Céline",middleName:null,surname:"Born",fullName:"Céline Born",slug:"celine-born"},{id:"139579",title:"Dr.",name:"Céline",middleName:null,surname:"Nkenfou",fullName:"Céline Nkenfou",slug:"celine-nkenfou"}]},{id:"37275",title:"Study of Mycobacterium Tuberculosis by Molecular Methods in Northeast Mexico",slug:"study-of-mycobacterium-tuberculosis-by-molecular-methods-in-northeast-mexico",totalDownloads:1580,totalCrossrefCites:0,signatures:"H. W. Araujo-Torres, J. A. Narvaez-Zapata, M. G. Castillo-Alvarez, MS. Puga-Hernandez, J. Flores-Gracia and M. A. Reyes-Lopez",authors:[{id:"112638",title:"Dr.",name:"Miguel Ángel",middleName:null,surname:"Reyes-López",fullName:"Miguel Ángel Reyes-López",slug:"miguel-angel-reyes-lopez"},{id:"112645",title:"Dr.",name:"José Alberto",middleName:null,surname:"Narváez-Zapata",fullName:"José Alberto Narváez-Zapata",slug:"jose-alberto-narvaez-zapata"},{id:"117929",title:"MSc.",name:"Hernán",middleName:null,surname:"Araujo-Torres",fullName:"Hernán Araujo-Torres",slug:"hernan-araujo-torres"},{id:"117930",title:"MSc.",name:"Guadalupe",middleName:null,surname:"Castillo-Alvarez",fullName:"Guadalupe Castillo-Alvarez",slug:"guadalupe-castillo-alvarez"},{id:"117932",title:"Dr.",name:"Juan",middleName:null,surname:"Flores-García",fullName:"Juan Flores-García",slug:"juan-flores-garcia"},{id:"144034",title:"Prof.",name:"María Del Socorro",middleName:null,surname:"Puga-Hernández",fullName:"María Del Socorro Puga-Hernández",slug:"maria-del-socorro-puga-hernandez"}]},{id:"37276",title:"Development of a Molecular Platform for GMO Detection in Food and Feed on the Basis of “Combinatory qPCR” Technology",slug:"development-of-a-molecular-platform-for-gmo-detection-in-food-and-feed-on-the-basis-of-combinatory-q",totalDownloads:1498,totalCrossrefCites:2,signatures:"Sylvia Broeders, Nina Papazova, Marc Van den Bulcke and Nancy Roosens",authors:[{id:"19865",title:"Dr.",name:"Marc",middleName:null,surname:"Van den Bulcke",fullName:"Marc Van den Bulcke",slug:"marc-van-den-bulcke"},{id:"114708",title:"Dr.",name:"Nancy",middleName:null,surname:"Roosens",fullName:"Nancy Roosens",slug:"nancy-roosens"},{id:"117801",title:"Dr.",name:"Nina",middleName:null,surname:"Papazova",fullName:"Nina Papazova",slug:"nina-papazova"},{id:"117804",title:"Dr.",name:"Sylvia",middleName:null,surname:"Broeders",fullName:"Sylvia Broeders",slug:"sylvia-broeders"}]},{id:"37277",title:"Overview of Real-Time PCR Principles",slug:"overview-of-real-time-pcr-principles",totalDownloads:9381,totalCrossrefCites:0,signatures:"Morteza Seifi, Asghar Ghasemi, Siamak Heidarzadeh, Mahmood Khosravi, Atefeh Namipashaki, Vahid Mehri Soofiany, Ali Alizadeh Khosroshahi and Nasim Danaei",authors:[{id:"49170",title:"Dr.",name:"Mahmood",middleName:null,surname:"Khosravi",fullName:"Mahmood Khosravi",slug:"mahmood-khosravi"},{id:"144349",title:"Ph.D.",name:"Morteza",middleName:null,surname:"Seifi",fullName:"Morteza Seifi",slug:"morteza-seifi"},{id:"144974",title:"Dr.",name:"Asghar",middleName:null,surname:"Ghasemi",fullName:"Asghar Ghasemi",slug:"asghar-ghasemi"},{id:"144976",title:"Dr.",name:"Siamak",middleName:null,surname:"Heidarzadeh",fullName:"Siamak Heidarzadeh",slug:"siamak-heidarzadeh"},{id:"145086",title:"MSc.",name:"Atefeh",middleName:null,surname:"Namipashaki",fullName:"Atefeh Namipashaki",slug:"atefeh-namipashaki"},{id:"145090",title:"MSc.",name:"Ali",middleName:null,surname:"Alizadeh Khosroshahi",fullName:"Ali Alizadeh Khosroshahi",slug:"ali-alizadeh-khosroshahi"},{id:"145091",title:"B.Sc.",name:"Vahid",middleName:null,surname:"Mehrisofiani",fullName:"Vahid Mehrisofiani",slug:"vahid-mehrisofiani"}]},{id:"37278",title:"PCR Advances Towards the Identification of Individual and Mixed Populations of Biotechnology Microbes",slug:"pcr-advances-towards-the-identification-of-individual-and-mixed-populations-of-biotechnology-microbe",totalDownloads:1754,totalCrossrefCites:0,signatures:"P. S. Shwed",authors:[{id:"114678",title:"Dr",name:"Philip",middleName:"S.",surname:"Shwed",fullName:"Philip Shwed",slug:"philip-shwed"}]},{id:"37279",title:"Lack of Evidence for Contribution of eNOS, ACE and AT1R Gene Polymorphisms with Development of Ischemic Stroke in Turkish Subjects in Trakya Region",slug:"lack-of-evidence-for-contribution-of-enos-ace-and-at1r-gene-polymorphisms-with-development-of-ischem",totalDownloads:1489,totalCrossrefCites:0,signatures:"Tammam Sipahi",authors:[{id:"114179",title:"Dr.",name:"Tammam",middleName:null,surname:"Sipahi",fullName:"Tammam Sipahi",slug:"tammam-sipahi"}]},{id:"37280",title:"Analysis of Genomic Instability and Tumor-Specific Genetic Alterations by Arbitrarily Primed PCR",slug:"analysis-of-genomic-instability-and-tumor-specific-genetic-alterations-by-arbitrarily-primed-pcr",totalDownloads:1171,totalCrossrefCites:0,signatures:"Nikola Tanic, Jasna Bankovic and Nasta Tanic",authors:[{id:"112962",title:"Dr.",name:"Nikola",middleName:null,surname:"Tanic",fullName:"Nikola Tanic",slug:"nikola-tanic"},{id:"118055",title:"Dr.",name:"Jasna",middleName:null,surname:"Bankovic",fullName:"Jasna Bankovic",slug:"jasna-bankovic"},{id:"118058",title:"Dr.",name:"Nasta",middleName:null,surname:"Tanic",fullName:"Nasta Tanic",slug:"nasta-tanic"}]},{id:"37281",title:"Analysis of Alternatively Spliced Domains in Multimodular Gene Products - The Extracellular Matrix Glycoprotein Tenascin C",slug:"analysis-of-alternatively-spliced-domains-in-multimodular-gene-products-the-extracellular-matrix-gly",totalDownloads:1718,totalCrossrefCites:0,signatures:"Ursula Theocharidis and Andreas Faissner",authors:[{id:"116612",title:"Prof.",name:"Fousseyni",middleName:null,surname:"Touré Ndouo",fullName:"Fousseyni Touré Ndouo",slug:"fousseyni-toure-ndouo"}]},{id:"37282",title:"Submicroscopic Human Parasitic Infections",slug:"submicroscopic-human-parasitic-infections",totalDownloads:971,totalCrossrefCites:0,signatures:"Fousseyni S. Toure Ndouo",authors:[{id:"118199",title:"Dr.",name:"Ursula",middleName:null,surname:"Theocharidis",fullName:"Ursula Theocharidis",slug:"ursula-theocharidis"},{id:"118203",title:"Dr.",name:"Andreas",middleName:null,surname:"Faissner",fullName:"Andreas Faissner",slug:"andreas-faissner"}]},{id:"37283",title:"Identification of Genetic Markers Using Polymerase Chain Reaction (PCR) in Graves' Hyperthyroidism",slug:"identification-of-genetic-markers-using-polymerase-chain-reaction-pcr-in-graves-hyperthyroidism",totalDownloads:1079,totalCrossrefCites:0,signatures:"P. Veeramuthumari and W. Isabel",authors:[{id:"112972",title:"Dr.",name:"P",middleName:null,surname:"Veeramuthumari",fullName:"P Veeramuthumari",slug:"p-veeramuthumari"},{id:"116558",title:"Dr.",name:"Isabel",middleName:null,surname:"W",fullName:"Isabel W",slug:"isabel-w"}]},{id:"37284",title:"Detection of Bacterial Pathogens in River Water Using Multiplex-PCR",slug:"detection-of-bacterial-pathogens-in-river-water-using-multiplex-pcr",totalDownloads:5213,totalCrossrefCites:1,signatures:"C. N. Wose Kinge, M. Mbewe and N. P. Sithebe",authors:[{id:"110823",title:"MSc.",name:"Constance",middleName:null,surname:"Wose Kinge",fullName:"Constance Wose Kinge",slug:"constance-wose-kinge"},{id:"139176",title:"Prof.",name:"Moses",middleName:null,surname:"Mbewe",fullName:"Moses Mbewe",slug:"moses-mbewe"},{id:"139178",title:"Dr.",name:"Patricia",middleName:null,surname:"Sithebe",fullName:"Patricia Sithebe",slug:"patricia-sithebe"}]},{id:"37285",title:"PCR-RFLP and Real-Time PCR Techniques in Molecular Cancer Investigations",slug:"pcr-rflp-and-real-time-pcr-techniques-in-molecular-cancer-investigations",totalDownloads:4743,totalCrossrefCites:0,signatures:"Uzay Gormus, Nur Selvi and Ilhan Yaylim-Eraltan",authors:[{id:"69292",title:"Prof.",name:"Uzay",middleName:null,surname:"Gormus",fullName:"Uzay Gormus",slug:"uzay-gormus"},{id:"110174",title:"Prof.",name:"Ilhan",middleName:null,surname:"Yaylim",fullName:"Ilhan Yaylim",slug:"ilhan-yaylim"},{id:"118373",title:"Dr.",name:"Nur",middleName:null,surname:"Selvi",fullName:"Nur Selvi",slug:"nur-selvi"}]}]},relatedBooks:[{type:"book",id:"2553",title:"Lipid Peroxidation",subtitle:null,isOpenForSubmission:!1,hash:"b39734aa940b2d63ae5e8773d3dd5280",slug:"lipid-peroxidation",bookSignature:"Angel Catala",coverURL:"https://cdn.intechopen.com/books/images_new/2553.jpg",editedByType:"Edited by",editors:[{id:"133493",title:"Prof.",name:"Angel",surname:"Catala",slug:"angel-catala",fullName:"Angel Catala"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"38477",title:"Lipid Peroxidation: Chemical Mechanism, Biological Implications and Analytical Determination",slug:"lipid-peroxidation-chemical-mechanism-biological-implications-and-analytical-determination",signatures:"Marisa Repetto, Jimena Semprine and Alberto Boveris",authors:[{id:"36452",title:"Dr.",name:"Marisa",middleName:"Gabriela",surname:"Repetto",fullName:"Marisa Repetto",slug:"marisa-repetto"}]},{id:"38517",title:"Lipid Oxidation in Homogeneous and Micro-Heterogeneous Media in Presence of Prooxidants, Antioxidants and Surfactants",slug:"lipid-oxidation-in-homogeneous-and-micro-heterogeneous-media-in-presence-of-prooxidants-antioxidants",signatures:"Vessela D. Kancheva and Olga T. Kasaikina",authors:[{id:"139075",title:"Prof.",name:"Vessela",middleName:"Deneva",surname:"Kancheva",fullName:"Vessela Kancheva",slug:"vessela-kancheva"},{id:"142775",title:"Prof.",name:"Olga",middleName:null,surname:"Kasaikina",fullName:"Olga Kasaikina",slug:"olga-kasaikina"}]},{id:"38468",title:"Lipid Peroxidation End-Products as a Key of Oxidative Stress: Effect of Antioxidant on Their Production and Transfer of Free Radicals",slug:"lipid-peroxidation-end-products-as-a-key-of-oxidative-stress-effect-of-antioxidant-on-their-producti",signatures:"Hanaa Ali Hassan Mostafa Abd El-Aal",authors:[{id:"140134",title:"Prof.",name:"Hanaa",middleName:"Ali",surname:"Hassan",fullName:"Hanaa Hassan",slug:"hanaa-hassan"}]},{id:"38472",title:"Iron Overload and Lipid Peroxidation in Biological Systems",slug:"iron-overload-and-lipid-peroxidation-in-biological-systems",signatures:"Paula M. González, Natacha E. Piloni and Susana Puntarulo",authors:[{id:"36192",title:"Dr.",name:"Susana",middleName:null,surname:"Puntarulo",fullName:"Susana Puntarulo",slug:"susana-puntarulo"}]},{id:"38469",title:"Trends in the Evaluation of Lipid Peroxidation Processes",slug:"trends-in-the-evaluation-of-lipid-peroxidation-processes",signatures:"Mihaela Ilie and Denisa Margină",authors:[{id:"47029",title:"Dr.",name:"Denisa",middleName:null,surname:"Margina",fullName:"Denisa Margina",slug:"denisa-margina"},{id:"49035",title:"Dr.",name:"Mihaela",middleName:null,surname:"Ilie",fullName:"Mihaela Ilie",slug:"mihaela-ilie"}]},{id:"38473",title:"Automation of Methods for Determination of Lipid Peroxidation",slug:"automation-of-methods-for-determination-of-lipid-peroxidation",signatures:"Jiri Sochor, Branislav Ruttkay-Nedecky, Petr Babula, Vojtech Adam, Jaromir Hubalek and Rene Kizek",authors:[{id:"16205",title:"Dr.",name:"Rene",middleName:null,surname:"Kizek",fullName:"Rene Kizek",slug:"rene-kizek"},{id:"16208",title:"Dr.",name:"Petr",middleName:null,surname:"Babula",fullName:"Petr Babula",slug:"petr-babula"},{id:"30300",title:"Dr.",name:"Jaromír",middleName:null,surname:"Hubálek",fullName:"Jaromír Hubálek",slug:"jaromir-hubalek"},{id:"142669",title:"Dr.",name:"Jiri",middleName:null,surname:"Sochor",fullName:"Jiri Sochor",slug:"jiri-sochor"},{id:"142676",title:"Dr.",name:"Branislav",middleName:null,surname:"Ruttkay-Nedecky",fullName:"Branislav Ruttkay-Nedecky",slug:"branislav-ruttkay-nedecky"},{id:"142677",title:"Dr.",name:"Vojtech",middleName:null,surname:"Adam",fullName:"Vojtech Adam",slug:"vojtech-adam"}]},{id:"38478",title:"Liposomes as a Tool to Study Lipid Peroxidation",slug:"liposomes-as-a-tool-to-study-lipid-peroxidation",signatures:"Biljana Kaurinovic and Mira Popovic",authors:[{id:"139916",title:"Prof.",name:"Mira",middleName:null,surname:"Popovic",fullName:"Mira Popovic",slug:"mira-popovic"},{id:"142369",title:"Prof.",name:"Biljana",middleName:null,surname:"Kaurinovic",fullName:"Biljana Kaurinovic",slug:"biljana-kaurinovic"}]},{id:"38457",title:"Liposomes as a Tool to Study Lipid Peroxidation in Retina",slug:"liposomes-as-a-tool-to-study-lipid-peroxidation-in-retina",signatures:"Natalia Fagali and Angel Catalá",authors:[{id:"133493",title:"Prof.",name:"Angel",middleName:null,surname:"Catala",fullName:"Angel Catala",slug:"angel-catala"},{id:"139988",title:"Dr.",name:"Natalia",middleName:null,surname:"Fagali",fullName:"Natalia Fagali",slug:"natalia-fagali"}]},{id:"38461",title:"The Effect of Plant Secondary Metabolites on Lipid Peroxidation and Eicosanoid Pathway",slug:"the-effect-of-plant-secondary-metabolites-on-lipid-peroxidation-and-eicosanoid-pathway",signatures:"Neda Mimica-Dukić, Nataša Simin, Emilija Svirčev, Dejan Orčić, Ivana Beara, Marija Lesjak and Biljana Božin",authors:[{id:"78766",title:"Dr.",name:"Biljana",middleName:null,surname:"Bozin",fullName:"Biljana Bozin",slug:"biljana-bozin"},{id:"140273",title:"Prof.",name:"Neda",middleName:null,surname:"Mimica-Dukic",fullName:"Neda Mimica-Dukic",slug:"neda-mimica-dukic"},{id:"142754",title:"MSc.",name:"Natasa",middleName:null,surname:"Simin",fullName:"Natasa Simin",slug:"natasa-simin"},{id:"142756",title:"BSc.",name:"Emilija",middleName:null,surname:"Jovin",fullName:"Emilija Jovin",slug:"emilija-jovin"},{id:"142757",title:"Dr.",name:"Dejan",middleName:null,surname:"Orcic",fullName:"Dejan Orcic",slug:"dejan-orcic"},{id:"156386",title:"Dr.",name:"Ivana",middleName:null,surname:"Beara",fullName:"Ivana Beara",slug:"ivana-beara"},{id:"156387",title:"Dr.",name:"Marija",middleName:null,surname:"Lesjak",fullName:"Marija Lesjak",slug:"marija-lesjak"}]},{id:"38471",title:"Repeatedly Heated Vegetable Oils and Lipid Peroxidation",slug:"repeatedly-heated-vegetable-oils-and-lipid-peroxidation",signatures:"Kamsiah Jaarin and Yusof Kamisah",authors:[{id:"140497",title:"Dr.",name:"Kamsiah",middleName:null,surname:"Jaarin",fullName:"Kamsiah Jaarin",slug:"kamsiah-jaarin"},{id:"140500",title:"Associate Prof.",name:"Yusof",middleName:null,surname:"Kamisah",fullName:"Yusof Kamisah",slug:"yusof-kamisah"}]},{id:"38456",title:"Effects of Hydroperoxide in Lipid Peroxidation on Dough Fermentation",slug:"effects-of-hydroperoxide-in-lipid-peroxidation-on-dough-fermentation",signatures:"Toshiyuki Toyosaki",authors:[{id:"139920",title:"Prof.",name:"Toshiyuki",middleName:null,surname:"Toyosaki",fullName:"Toshiyuki Toyosaki",slug:"toshiyuki-toyosaki"}]},{id:"38460",title:"Modification of Fatty Acid Composition in Meat Through Diet: Effect on Lipid Peroxidation and Relationship to Nutritional Quality – A Review",slug:"modification-of-fatty-acid-composition-in-meat-through-diet-effect-on-lipid-peroxidation-and-relatio",signatures:"Gema Nieto and Gaspar Ros",authors:[{id:"141016",title:"Dr.",name:"Gema",middleName:null,surname:"Nieto",fullName:"Gema Nieto",slug:"gema-nieto"},{id:"141332",title:"Prof.",name:"Gaspar",middleName:null,surname:"Ros",fullName:"Gaspar Ros",slug:"gaspar-ros"}]},{id:"38458",title:"Lipid Peroxidation After Ionizing Irradiation Leads to Apoptosis and Autophagy",slug:"lipid-peroxidation-after-ionizing-irradiation-leads-to-apoptosis-and-autophagy",signatures:"Juliann G. Kiang, Risaku Fukumoto and Nikolai V. Gorbunov",authors:[{id:"157452",title:"Dr.",name:"Juliann",middleName:null,surname:"Kiang",fullName:"Juliann Kiang",slug:"juliann-kiang"},{id:"158709",title:"Dr.",name:"Risaku",middleName:null,surname:"Fukumoto",fullName:"Risaku Fukumoto",slug:"risaku-fukumoto"},{id:"158710",title:"Dr.",name:"Nikolai",middleName:null,surname:"Gorbunov",fullName:"Nikolai Gorbunov",slug:"nikolai-gorbunov"}]},{id:"38467",title:"Tissue Occurrence of Carbonyl Products of Lipid Peroxidation and Their Role in Inflammatory Disease",slug:"tissue-occurrence-of-carbonyl-products-of-lipid-peroxidation-and-their-role-in-inflammatory-disease",signatures:"Maria Armida Rossi",authors:[{id:"148504",title:"Prof.",name:"Maria",middleName:null,surname:"Rossi",fullName:"Maria Rossi",slug:"maria-rossi"}]},{id:"38465",title:"The Role of Physical Exercise on Lipid Peroxidation in Diabetic Complications",slug:"the-role-of-physical-exercise-on-lipid-peroxidation-in-diabetic-complications",signatures:"Yaşar Gül Özkaya",authors:[{id:"142843",title:"Dr.",name:"Y. Gul",middleName:null,surname:"Ozkaya",fullName:"Y. Gul Ozkaya",slug:"y.-gul-ozkaya"}]},{id:"38466",title:"Reactive Oxygen Species Act as Signaling Molecules in Liver Carcinogenesis",slug:"reactive-oxygen-species-act-as-signaling-molecules-in-liver-carcinogenesis",signatures:"María Cristina Carrillo, María de Luján Alvarez, Juan Pablo Parody, Ariel Darío Quiroga and María Paula Ceballos",authors:[{id:"142215",title:"PhD.",name:"Maria Cristina",middleName:null,surname:"Carrillo",fullName:"Maria Cristina Carrillo",slug:"maria-cristina-carrillo"},{id:"142855",title:"Dr.",name:"Maria De Luján",middleName:null,surname:"Alvarez",fullName:"Maria De Luján Alvarez",slug:"maria-de-lujan-alvarez"},{id:"142858",title:"BSc.",name:"Juan Pablo",middleName:null,surname:"Parody",fullName:"Juan Pablo Parody",slug:"juan-pablo-parody"},{id:"142859",title:"Dr.",name:"Ariel Darío",middleName:null,surname:"Quiroga",fullName:"Ariel Darío Quiroga",slug:"ariel-dario-quiroga"},{id:"142861",title:"BSc.",name:"Maria Paula",middleName:null,surname:"Ceballos",fullName:"Maria Paula Ceballos",slug:"maria-paula-ceballos"}]},{id:"38459",title:"Lipid Peroxidation and Antioxidants in Arterial Hypertension",slug:"lipid-peroxidation-and-antioxidants-in-arterial-hypertension",signatures:"Teresa Sousa, Joana Afonso, António Albino-Teixeira and Félix Carvalho",authors:[{id:"131252",title:"Prof.",name:"Félix",middleName:null,surname:"Carvalho",fullName:"Félix Carvalho",slug:"felix-carvalho"},{id:"140800",title:"Prof.",name:"António",middleName:null,surname:"Albino-Teixeira",fullName:"António Albino-Teixeira",slug:"antonio-albino-teixeira"},{id:"142410",title:"Prof.",name:"Teresa",middleName:null,surname:"Sousa",fullName:"Teresa Sousa",slug:"teresa-sousa"},{id:"142411",title:"MSc.",name:"Joana",middleName:null,surname:"Afonso",fullName:"Joana Afonso",slug:"joana-afonso"}]},{id:"38476",title:"Lipid Peroxidation and Reperfusion Injury in Hypertrophied Hearts",slug:"lipid-peroxidation-and-reperfusion-injury-in-hypertrophied-hearts",signatures:"Juliana C. Fantinelli, Ignacio A. Pérez Núñez, Luisa F. González Arbeláez and Susana M. Mosca",authors:[{id:"98613",title:"Dr.",name:"Susana",middleName:null,surname:"Mosca",fullName:"Susana Mosca",slug:"susana-mosca"}]},{id:"38455",title:"Lipid Peroxidation by-Products and the Metabolic Syndrome",slug:"lipid-peroxidation-by-products-and-the-metabolic-syndrome",signatures:"Nicolas J. Pillon and Christophe O. Soulage",authors:[{id:"139163",title:"Dr.",name:"Nicolas",middleName:"Jean",surname:"Pillon",fullName:"Nicolas Pillon",slug:"nicolas-pillon"},{id:"139829",title:"Dr.",name:"Christophe",middleName:null,surname:"Soulage",fullName:"Christophe Soulage",slug:"christophe-soulage"}]},{id:"38475",title:"Region Specific Vulnerability to Lipid Peroxidation in the Human Central Nervous System",slug:"region-specific-vulnerability-to-lipid-peroxidation-in-the-human-central-nervous-system",signatures:"Alba Naudí, Mariona Jové, Victòria Ayala, Omar Ramírez, Rosanna Cabré, Joan Prat, Manuel Portero-Otin, Isidre Ferrer and Reinald Pamplona",authors:[{id:"139955",title:"Prof.",name:"Reinald",middleName:null,surname:"Pamplona",fullName:"Reinald Pamplona",slug:"reinald-pamplona"}]},{id:"38474",title:"Role of Lipid Peroxidation in the Pathogenesis of Age-Related Cataract",slug:"role-of-lipid-peroxidation-in-the-pathogenesis-of-age-related-cataract",signatures:"Bojana Kisic, Dijana Miric, Lepsa Zoric and Aleksandra Ilic",authors:[{id:"139383",title:"Prof.",name:"Bojana",middleName:null,surname:"Kisic",fullName:"Bojana Kisic",slug:"bojana-kisic"},{id:"150937",title:"Prof.",name:"Dijana",middleName:null,surname:"Miric",fullName:"Dijana Miric",slug:"dijana-miric"},{id:"150938",title:"Prof.",name:"Lepsa",middleName:null,surname:"Zoric",fullName:"Lepsa Zoric",slug:"lepsa-zoric"},{id:"150939",title:"Dr.",name:"Aleksandra",middleName:null,surname:"Ilic",fullName:"Aleksandra Ilic",slug:"aleksandra-ilic"}]},{id:"38462",title:"Lipid Peroxidation in Hepatic Fibrosis",slug:"lipid-peroxidation-in-hepatic-fibrosis",signatures:"Ichiro Shimizu, Noriko Shimamoto, Katsumi Saiki, Mai Furujo and Keiko Osawa",authors:[{id:"142420",title:"Dr.",name:"Ichiro",middleName:null,surname:"Shimizu",fullName:"Ichiro Shimizu",slug:"ichiro-shimizu"}]},{id:"38463",title:"Use of CoA Biosynthesis Modulators and Selenoprotein Model Substance in Correction of Brain Ischemic and Reperfusion Injuries",slug:"use-of-coa-biosynthesis-modulators-and-selenoprotein-model-substance-in-correction-of-brain-ischemic",signatures:"Nina P. Kanunnikova, Natalya Z. Bashun and Andrey G. Moiseenok",authors:[{id:"142487",title:"Prof.",name:"Nina",middleName:null,surname:"Kanunnikova",fullName:"Nina Kanunnikova",slug:"nina-kanunnikova"},{id:"142491",title:"Dr.",name:"Natalya",middleName:null,surname:"Bashun",fullName:"Natalya Bashun",slug:"natalya-bashun"},{id:"142503",title:"Prof.",name:"Andrey",middleName:null,surname:"Moiseenok",fullName:"Andrey Moiseenok",slug:"andrey-moiseenok"}]},{id:"38464",title:"Lipid Peroxidation and Polybrominated Diphenyl Ethers – A Toxicological Perspective",slug:"lipid-peroxidation-and-polybrominated-diphenyl-ethers-a-toxicological-perspective",signatures:"Mary C. Vagula and Elisa M. Konieczko",authors:[{id:"141806",title:"Dr.",name:"Mary",middleName:null,surname:"Vagula",fullName:"Mary Vagula",slug:"mary-vagula"},{id:"150947",title:"Prof.",name:"Elisa",middleName:null,surname:"Konieczko",fullName:"Elisa Konieczko",slug:"elisa-konieczko"}]}]}]},onlineFirst:{chapter:{type:"chapter",id:"63750",title:"Serotonin Reuptake Inhibitors and Their Role in Chronic Pain Management",doi:"10.5772/intechopen.80711",slug:"serotonin-reuptake-inhibitors-and-their-role-in-chronic-pain-management",body:'\nChronic pain is recognized today as a disease [1], affects almost 20% of the population [2], and represents a significant cause of disability bringing along high secondary social costs. The management of chronic pain involves pharmacological and interventional tools and become a priority for healthcare systems. This chapter aims to summarize the role of serotonin reuptake inhibitors (SRI) in the treatment of chronic pain. SRI includes selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI).
\nDefined as the pain that lasts more than 3 months, frequent after the disappearance of the causal factor, chronic pain shows numerous risk factors (socio-demographic, biological, clinical, and psychological). Thus, most affected are females, older people, and people with low socio-economic level. A significant risk for developing chronic pain is the pain itself (acute and chronic at other sites), and also are incriminated the geographical background, occupational factors, and the history of abuse and violence. Neuroimaging studies have already proved the changes in the brain with severe pain, reversible with proper treatment, and also suggested its importance for preventing the chronicization of pain [3]. The treatment of chronic pain is multi/interdisciplinary and multimodal, targeting different mechanisms of pain. We summarized some critical pain syndromes, which benefit from the SRI medication.
\nDiabetes mellitus affects billions of people worldwide. The painful diabetic neuropathy (PDPN) occurs in 20% of diabetes patients during the disease. Risk factors include age, hypertension, obesity, alcohol abuse, and smoking.
\nPathogenesis implies endoneurial microangiopathy and axonal loss, especially in sensory nerves. Aldose reductase activation by increasing polyol flux and the deposition of advanced glycated end-products are the primary determinants of PDPN. Secondary ischemia leads to enhanced oxidative stress and high production of free radicals, which leads to nerve damage [4].
\nClinical PDPN may present as burning, stabbing, dull and aching, or sharp pain. In some instances, allodynia (painful response to a normally non-noxious stimulus) might accompany pain. PDPN is symptomatic mainly in the lower limbs and progresses proximally. Patients with PDPN show skin changes and loss of sensory that could lead further to diabetic ulcers.
\nThe medication of painful diabetic neuropathy includes duloxetine, venlafaxine, tricyclic antidepressants (TAD), oxcarbazepine, and tapentadol. Overall, the quality of life in patients with PDPN is poor [5].
\nFibromyalgia (FM) is a syndrome composed of widespread chronic pain, muscle fatigue, and functional symptoms. It shows a genetic predisposition, but environmental factors play a prominent place during the disease. FM pathogenesis involves modified inflammatory response and oxidative stress [6].
\nDiagnosis is difficult because of the variety of clinical symptoms—75% of these patients do not meet the inclusion criteria, thus often they lack the diagnosis. Besides, these patients develop sleep disturbances and sexual dysfunction, altering further the quality of life.
\nThe current evidence suggest for FM management antidepressants, cardiovascular exercise, and cognitive behavioral therapy [7]. Meta-analysis results agree that the medication approved by FDA—milnacipran—and duloxetine are effective in FM while there are concerns that the results showed only a moderate effect on pain and sleep, and no impact on fatigue [8].
\nTension-type headache (TTH) is a typical headache (up to 78%), caused by the contractions of muscles of the scalp, neck, and jaw, and triggered mainly by stress and emotional conflicts. It is described as a moderate pressure applied to the frontal area, around the head or neck, and according to its frequency is classified as infrequent, frequent, and chronic.
\nChronic TTH results as a consequence of sensitization of the pain pathway due to persistent pericranial myofascial nociceptive input. This TTH shows a frequency of at least 15 days/month for at least 3 months. If nausea and vomiting are present, exclude the diagnosis of TTH. Photophobia may occur in TTH.
\nTreatment of the acute episodes of TTH includes nonsteroidal anti-inflammatory drugs and acetaminophen, while their prevention associates pharmacologic and non-pharmacologic (physical and psychologic therapy) interventions. Tricyclic antidepressants (amitriptyline) are the most studied drugs in TTH, but new studies showed efficacy for other antidepressants including SRI—citalopram, sertraline, venlafaxine, and paroxetine [9].
\nSomatoform pain (SP) is the primary symptom in an ambiguous and unclarified category called somatization spectrum disorders (SSD), defined as the displaying of somatic complaints as a result of social stress. It shows a growing incidence (up to 60%) and is a symptom generally unexplained by the medical condition of these patients (which must be ruled out). The symptomatology—headache and musculoskeletal pain—overlaps with other chronic pain syndromes and may be associated with psychiatric symptoms (depression, anxiety, personality disorders) and thus makes the diagnosis difficult. The mechanism of this condition is a subject of debate, but a genetic predisposition plus an altered interpersonal relationship in childhood and adolescence are the determining factors [10].
\nTreatment is focused on psychotherapy and modulation of interpersonal relations, by learning to develop robust, safe, and supportive social relationships. Besides, acupuncture and massage proved efficacy. Medication includes TADs and SSRIs [11].
\nDue to the association between chronic pain states and depression and also due to the continuous need and search for effective analgesic drugs, antidepressants have long been considered for the treatment of chronic pain. Some antidepressants are useful in the management of pain syndromes showing analgesic effects, but not all antidepressants have analgesic properties [12]. TADs are recognized to have analgesic effects in doses lower than the antidepressant ones. However, frequent side effects preclude their widespread use.
\nConsequently, newer generations of antidepressants, like SSRIs and SNRIs, have been studied in chronic pain management. For SSRIs, efficiency in chronic pain conditions has been debated, and results are still inconclusive. It is felt that antidepressants with both noradrenergic and serotoninergic activities are superior analgesics compared to drugs that possess only serotoninergic activity [13].
\nCurrently available SSRIs are fluoxetine, sertraline, paroxetine, citalopram, and escitalopram. Fluvoxamine is approved for the treatment of obsessive-compulsive disorders but has sometimes been used off-label for the treatment of depression. SSRIs are currently approved and used for the treatment of a wide range of diseases: depression, anxiety and panic disorders, obsessive-compulsive disorders, post-traumatic stress disorder, premenstrual dysphoric syndrome, dysthymia, irritable bowel syndrome, eating disorders, alcohol abuse, and some personality disorders [14].
\nSSRIs utility for the treatment of chronic pain has been questioned but seems attractive due to their better side-effect profile compared to first-generation antidepressants like TADs, as SSRIs selectively block serotonin reuptake (reabsorption in the synaptic cleft).
\nHow could SSRIs be useful in chronic pain management? Do they possess both antidepressant and intrinsic analgesic properties?
\nEven though widely prescribed, the mechanism of action of SSRIs is not yet fully understood. The traditional theories claim the fact that antidepressant drugs act by influencing certain brain neurotransmitters [15]. Serotonin (5-HT) is one of the neurotransmitters which carry signals between neurons. The monoamine signaling theory of depression explains how SSRIs and other antidepressants work at the synaptic level by inhibiting the reuptake of one or several neurotransmitters, an effect which is almost immediate and leads to the increase of the extracellular level of the mediator. SSRIs are selective inhibitors of the presynaptic 5-HT reuptake transporter (SERT) that leads to an acute increase in serotonin concentrations in the synaptic cleft. This effect does not explain why antidepressant drugs work 2–4 weeks after treatment commencement, which might be better explained by receptor downregulation and delayed desensitization of presynaptic serotonin receptors [16]. Recent findings also suggest changes in brain-derived neurotrophic factor expression, which might even lead to SSRI antidepressant effect. Another newer theory suggests that SSRIs impact brain levels of allopregnanolone, enhancing gamma-amino butyric functions in the brain [14]. Apart from monoamine neurotransmitter’s imbalance, the inflammatory theory of depression claims the increased serum levels of proinflammatory mediators in the depressed patients [17]. As inflammation is the well-known cause of acute and some type of chronic pain, proinflammatory mediators play the capital role in initiating nociception and peripheral sensitization. In vitro experimental studies and early in vivo studies suggested that SSRIs could inhibit the release of TNF-α, interferon γ, interleukin 1β, and free radical superoxide [16, 18]. Probably one of the most plausible humoral links between chronic pain conditions and depression is inflammation. If SSRIs have intrinsic anti-inflammatory and anti-oxidative properties and could modulate inflammatory processes, then this could be an explanation for their therapeutic effect in chronic pain management. The detailed specificity of action for this mechanism remains unknown [19]. Intrinsic antihyperalgesic effects in animal models have recently been described for SSRIs [20, 21, 22, 23].
\nPossible side effects observed during antidepressant treatment with SSRIs also need to be considered when prescribing SSRIs for chronic pain management.
\nThese side effects include [12, 14, 24]:
Drowsiness, dry mouth, blurred vision, dizziness
Gastrointestinal effects: nausea, diarrhea or constipation, vomiting
Central nervous system effects: insomnia, agitation or restlessness, headache, tremors, increased sweating, rarely extrapyramidal symptoms, anorexia
Syndrome of inappropriate antidiuretic hormone secretion with hyponatremia, somnolence, delirium, confusion
Sexual dysfunction
Weight gain
Platelet dysfunction and increased risk of bleeding
Drug interactions due to the concomitant hepatic metabolism involving the cytochrome P450
Safety issues in pregnancy
Serotonin syndrome
Suicide might be a risk occurring early in the treatment, even though larger epidemiological studies do not confirm this assumption [14].
\nSSRIs discontinuation syndrome is characterized by sensory and gastrointestinal symptoms, dizziness, lethargy, and sleep disturbances [25].
\nFluoxetine (Prozac™, Sarafem™) has been one of the first SSRIs available for the treatment of depression. Its use for chronic pain management has been highlighted in several clinical trials including modest numbers of patients (Table 1). For chronic tension-type headache, fluoxetine administered in 20 mg daily dose is equally efficient to desipramine [26]. For the treatment of painful diabetic neuropathy, fluoxetine is no more effective than placebo and ameliorates pain in 48% of the patients, especially the depressed ones [27]. For somatoform pain disorders, the analgesic effect is related to treatment duration and is related to its antidepressant effect as depressive patients show greater improvement compared to non-depressed ones [28]. Fluoxetine was found to be efficient for the treatment of fibromyalgia when compared to placebo or amitriptyline [29, 30].
\n\n | Study | \nChronic pain condition | \nDose used for chronic pain (mg) | \nNo patients | \nComparator | \nEfficiency | \n
---|---|---|---|---|---|---|
Fluoxetine 10–80 mg/day for depression [14] | \nWalker et al. [26] | \nChronic tension-type headache | \n20 | \n25 | \nDesipramine | \nEqually efficient | \n
Max et al. [27] | \nDiabetic neuropathy | \n40 | \n46 | \nPlacebo | \nEqually efficient | \n|
Luo et al. [28] | \nSomatoform pain disorders | \n20 | \n80 | \nPlacebo | \nEfficient for depressed patients | \n|
Goldenberg et al. [29] | \nFibromyalgia | \n20 | \n19 | \nAmitriptyline | \nEffective | \n|
Arnold et al. [30] | \nFibromyalgia | \n45 ± 25 | \n60 | \nPlacebo | \nEffective | \n
Randomized controlled trials for fluoxetine in chronic pain management.
Fluvoxamine (Luvox™) is currently used for the treatment of obsessive-compulsive disorders, and the therapeutic dose varies widely between 50 and 300 mg. Non-depressed patients with severe chronic tension-type headache respond to fluvoxamine 50–100 mg daily [31], and it is efficient in central post-stroke pain, cancer pain, and osteoarthritis [32, 33, 34]. However, for chronic cancer pain, its beneficial effect has not yet been proven [35].
\nSertraline (Zoloft™) is recommended in single daily doses of 50–200 mg for the treatment of depression. In small sample size studies, it has proven to be efficient in non-cardiac chronic chest pain and chronic pelvic pain of prostatic origin in men [36, 37], but not in women with chronic pelvic pain [38].
\nParoxetine (Paxil™, Seroxat™) is one of the most extensively studied SSRI for chronic pain management (Table 2). For tension-type daily headache, two studies failed to prove any beneficial effect [39, 40]. Foster et al. suggested that by extending treatment periods up to 3–9 months, patients may benefit [41]. For chronic low back pain, doses of 20 mg are less efficient than maprotiline, and the effects are similar to placebo [42, 43]. In fibromyalgia, paroxetine improves overall symptomatology, but the effect on pain is less robust [44]. Paroxetine has been shown to be useful for the treatment of diabetic peripheral neuropathy, but not more efficient than imipramine [45]. In a mixed study comparing paroxetine and citalopram versus gabapentin, the comparable efficiency of these two SSRIs with gabapentin was shown [46].
\n\n | Study | \nChronic pain condition | \nDose used for chronic pain (mg) | \nNo of patients | \nComparator | \nEfficiency | \n
---|---|---|---|---|---|---|
Paroxetine 10–50 mg daily for depression [14] | \nLangemark and Olesen [39] | \nChronic tension-type headache | \n20–30 | \n50 | \nSulpiride | \nLess efficient | \n
Holroyd et al. [40] | \nChronic headache, non-responding to amitriptyline | \nUp to 40 | \n31 | \nPlacebo | \nModest effect | \n|
Foster and Bafaloukos [41] | \nChronic daily headache | \n10–50 | \n48 | \nPlacebo | \nEfficient when used for 3–9 months | \n|
Dickens et al. [42] | \nChronic low back pain | \n20 | \n91 | \nPlacebo | \nNot efficient | \n|
Atkinson et al. [43] | \nChronic low back pain | \n20 | \n74 | \nMaprotiline | \nLess efficient | \n|
Patkar et al. [44] | \nFibromyalgia | \n12.5–2.5 mg | \n116 | \nPlacebo | \nInconclusive | \n|
Sindrup et al. [45] | \nDiabetic peripheral neuropathy | \n40 | \n29 | \nPlacebo and imipramine | \nEfficient compared to placebo, less efficient compared to imipramine | \n|
Giannopoulos et al. [52] | \nDiabetic peripheral neuropathy | \n20–40 | \n101 | \nCitalopram or paroxetine versus gabapentin | \nComparable efficiency | \n
Randomized controlled trials for paroxetine in chronic pain management.
Citalopram (Celexa™, Cipramil™) is administered in 10–80 mg dose once daily for the treatment of depression (Table 3). It has been investigated for the treatment of fibromyalgia and chronic tension-type headache, with no beneficial results [47, 48, 49], while for somatoform pain disorders it has only moderate analgesic effect [50, 51, 52].
\n\n | Study | \nChronic pain condition | \nDose used for chronic pain (mg) | \nNo of patients | \nComparator | \nEfficiency | \n|
---|---|---|---|---|---|---|---|
Citalopram 10–80 mg for depression [14] | \nNørregaard et al. [46] | \nFibromyalgia | \n20–40 | \n43 | \nPlacebo | \nNo effect | \n|
Anderberg et al. [47] | \nFibromyalgia | \n20–40 | \n40 | \nPlacebo | \nInconclusive | \n||
Aragona et al. [48] | \nSomatoform pain disorder | \n20 | \n35 | \nReboxetine | \nModerate effect | \n||
Bendsten et al. [49] | \nChronic tension-type headache | \n20 | \n40 | \nPlacebo and amitriptyline | \nNo significant effect | \n||
Viazis et al. [50] | \nGastroesophageal reflux disease | \n20 | \n63 | \nEfficient when administered with proton pump inhibitors | \n|||
Roohafza et al. [51] | \nPediatric functional abdominal pain | \n20 | \n86 | \nPlacebo | \nEffective | \n||
Giannopoulos et al. [52] | \nDiabetic peripheral neuropathy | \n20–40 | \n101 | \nCitalopram or paroxetine versus gabapentin | \nComparable efficiency | \n
Randomized controlled trials for citalopram in chronic pain management.
Escitalopram (Cipralex™, Lexapro™) has antidepressive effects in 10–20 mg daily dose. For chronic low back pain, citalopram has similar results compared to duloxetine [53]. It has pain-relieving effects in painful diabetic neuropathy and somatoform disorders [54, 55]. For the treatment of pain symptoms associated with depression, escitalopram is equally effective with nortriptyline [56].
\nSNRIs are first-line antidepressants known to inhibit the reuptake of serotonin and norepinephrine almost exclusively by binding to their transporters (SERT and NET). This category includes drugs with very different chemical structure and includes venlafaxine, desvenlafaxine, duloxetine, milnacipran, and levomilnacipran.
\nSNRIs show different pharmacokinetics and dynamics and also different affinity to SERT and NET with consequences on their therapeutic actions (Table 4).
\nSide effects of SNRIs are common to all antidepressants, but these drugs add dry mouth and constipation due to increased levels of noradrenaline. The risk of withdrawal because of side effects, in patients with chronic pain, was highest for milnacipran and followed by venlafaxine and duloxetine [57].
\nVenlafaxine (Effexor™) is an SNRI with mixed action on amine reuptake. When administrated in low doses, it inhibits SERT and at higher doses NAT. It is indicated for major depressive disorder (MDD) and also for anxiety, panic disorders, and social phobia management.
\nAn experimental study showed its antihyperalgesic effect after a single administration in a diabetic neuropathic pain model, a result reversed by pretreatment with yohimbine and chloroamphetamine, but not by naloxone [58].
\nLong ago, a short case report raised attention to the potential beneficial effect of venlafaxine in chronic pain management [59], and later others confirmed its beneficial effects in managing neuropathic pain: peripheral neuropathy, postherpetic neuropathy, headache, and multiple sclerosis. In a systematic review on neuropathic pain, the authors found four trials (high quality evidence): two with positive results at doses of 150–225 mg venlafaxine ER daily and two with negative results (lower doses). The number needed to treat (NNT) was 6.4 and the number needed to harm (NNH) was 11.8 [60].
\nIn elderly patients with low back pain and depression, 150 mg venlafaxine showed efficacy, but the authors suggested that patients who did not respond to small doses may benefit from dose augmentation after a 2-week period [61].
\nVenlafaxine may be useful in the treatment of spinal cord injury (SCI) associated with MDD because this medication improved SCI-related disability and pain. Still, further trials are needed to determine optimal doses and efficiency in patients with SCI without MDD [62, 63].
\nStudies in patients with taxane-oxaliplatin-induced neurotoxicity showed clinical improvement after venlafaxine (37.5 mg bid) [64], and further studies are in progress [65].
\nVenlafaxine had good results in acute pain; in patients with cancer breast surgery, the preoperative administration of 37.5 mg venlafaxine reduced the postoperative opioid consumption and the incidence of chronic postoperative pain at 6 months [66].
\nA former Cochrane meta-analysis reported little evidence to support the recommendation of venlafaxine in neuropathic pain management and noted that venlafaxine promoted fatigue, nausea, dizziness, and somnolence with a low incidence [67].
\nEventually, two recent reviews (11 and 13 trials) found that venlafaxine was beneficial in neuropathic pain management with good tolerability claiming the necessity for further research to expand these findings [68, 69]. There are contradictory findings in these recent reviews, but there is need for further good quality evidence.
\nDesvenlafaxine (Pristiq™) is the third SNRI with FDA approval and only indication for MDD management (50–400 mg daily). The daily recommended dose is 50 mg. Desvenlafaxine is the salt of an active metabolite of venlafaxine, and the ER form allows 1 day administration. It presents a good bioavailability (Table 4) and shows a low binding to plasma proteins (30%). Desvenlafaxine binds to SERT 10 times more than to NAT and also has a weak affinity for dopamine transporter. Adverse effects are dose-dependent and typical to all antidepressants. Doses of 200–400 mg showed efficacy in DPN management, with effect sizes similar to duloxetine [70] and with increased side effects at higher doses. At the moment, there is a lack of evidence to support the use of desvenlafaxine in chronic pain management.
\nDuloxetine (Cymbalta™; DLX) is probably the most used drug from this class of antidepressants. Aside from MDD and urinary incontinence, duloxetine is indicated for anxiety disorder, chronic pain in diabetic neuropathy, fibromyalgia, musculoskeletal pain, and osteoarthritis. DLX is a potent SNRI, with a high affinity for both SERT and NAT. It has a moderate bioavailability, with an elimination half-time of 12 h. It is metabolized in the liver and does not possess any active metabolite. Duloxetine exerts antihyperalgesic and allodynic effects, by impairing nociception at a peripheral level (blocks NaV 1.7 current) and by inhibiting neuronal firing [71]. With acute administration, DLX leads to elevated levels of NA and 5-HT, and with chronic treatment, it does not affect further basal levels of these monoamines [72]. Even if the significant pain-relieving effect was found after 7 weeks of treatment [73], others showed that patients treated with DLX for OA knee pain or low lumbar pain who have <10% reduction in pain after 4 weeks treatment have low chance to reach moderate pain reduction by the end of 12 weeks [74]. DLX’s recommended dose for the first week is 30 mg, raising the dose to 60 mg in the second week in order to avoid a high incidence of side effects.
\nBecause of interfering with platelet function, it is indicated to stop its administration 4 days before surgery.
\nData from animal pain models and clinical studies on DLX administration in perioperative setting (spine, knee, breast surgery) suggested its analgesic effects. Pre- and postoperative duloxetine reduced 24-h opioid consumption, delayed first analgesic requirement, and reduced incidence of chronic postoperative pain at 6 months, being of primary interest for patients with preoperative chronic pain and spine surgery [75, 76, 77]; results from ongoing studies will respond to questions remained unanswered. Duloxetine shows good tolerability with dizziness and nausea, dry mouth, and constipation, as more frequent side effects [78].
\nWhile duloxetine proved its efficacy in chronic nociceptive/neuropathic pain [79, 80, 81, 82, 83] (Table 5), it is yet unrevealed its possible impact on acute postoperative pain and chronic postoperative pain.
\nSNRI | \nBioavailability (%) | \nElimination half life | \nElimination | \nSERT affinity | \nNAT affinity | \nActive metabolite | \n
---|---|---|---|---|---|---|
Venlafaxine | \n45 | \n5 h (IR) 11 h (ER) | \nRenal | \nHigh | \nLow | \nYes | \n
Duloxetine IR | \n50 | \n12 h | \nRenal + feces | \nHigh | \nHigh | \nNo | \n
Milnacipran | \n85 | \n8 h | \nRenal (55% unchanged) | \nModerate | \nModerate | \nNo | \n
Desvenlafaxine | \n80 | \n11 h (IR) 13–14 h (ER) | \nRenal (45% unchanged) at 72 h | \nHigh | \nLow | \nNo | \n
Levomilnacipran | \n92 | \n12 h | \nRenal 58% unchanged | \nLow | \nHigh | \nNo | \n
SNRIs pharmacokinetics and pharmacodynamics.
SERT, serotonin transporter; NAT, noradrenaline transporter; IR, immediate release; ER, extended release.
Study | \nPathology | \nNo trials | \nNumber of patients | \nFindings | \n
---|---|---|---|---|
Lunn et al. [79] 60 mg | \nDiabetes fibromyalgia | \n14 8-DPN; 6-FM | \n6407 | \nIn both category showed efficacy DPN-NNT 5 FM-NNT 8 | \n
Quilici et al. [80] | \nDiabetes | \n11 | \n679 | \nEffective in DPN NNT = 5 Good toleration Superior to placebo Discontinuation due to AE | \n
Wang et al. [81] 60/120 mg (QD) | \nKnee osteoarthritis | \n3 | \n1011 | \nSignificant pain reduction Improved function Reported “acceptable” AE | \n
Lee and Song [82] | \nFibromyalgia | \n9 | \n5140 | \nResults showed equal efficacy and tolerability | \n
Hauser et al. [83] | \nFibromyalgia | \n10 | \n6038 | \nSmall benefit over placebo | \n
Meta-analysis for duloxetine in chronic pain management.
QD, quaque die; DLX, duloxetine; MLC, milnacipran; DPN, diabetes polyneuropathy; NNT, number needed to treat; FM, fibromyalgia; AE, adverse effect.
Milnacipran (Savella™) described in 1998 by Briley as a potent SNRI that showed similar inhibition on both monoamine re-uptakes, in vitro and in vivo, was approved in Europe for the treatment of depression. It did not link to alpha adrenoreceptors, muscarinic cholinergic, and histaminic receptors and showed no effect on beta-adrenergic receptors sensitivity, thus having reduced side effects. The drug has an excellent bioavailability with a mean peak plasma concentration reached between 0.5 and 4 h after the oral administration. About 13% binds to plasma proteins and is wholly eliminated after 36 h [84]. Studies on the efficacy of milnacipran in psychiatric patients revealed its significant superiority when compared to SSRIs. Most frequent adverse effects were nausea, dry mouth, and headaches [85]. Milnacipran has FDA approval for the management of fibromyalgia.
\nIn 2006, Obata et al. found that intrathecal administration of milnacipran reduced allodynia in a rat neuropathic pain model [86].
\nOther experimental data confirmed these findings regarding milnacipran’s antiallodynic and antihyperalgesic effects [87] and showed its effectiveness in treating allodynia in vincristine-induced neuropathic pain [88].
\nIn a Cochrane meta-analysis, Cording et al. analyzed six studies (4238 patients) that compared milnacipran 100/200 mg with placebo in fibromyalgia. By using a “conservative” method of analysis, they found 26% positive response with milnacipran as compared to 19% for placebo and an increased rate of side effects [89].
\nDespite the evidence that milnacipran (100 or 200 mg) was found to be useful in neuropathic pain, as compared with placebo, Derry et al.’s meta-analysis did not obtain enough data to confirm former data and support its recommendation in chronic neuropathic pain [90]. Future trials are needed to establish milnacipran’s possible favorable effects in pain management.
\nLevomilnacipran (Fetzima™) is the enantiomer of milnacipran with the highest activity, and its primary indication is MDD. At usual doses, this drug is known to possess a higher potency for norepinephrine (twofold) reuptake inhibition, as compared with 5-HT [91]; but with higher doses, it showed equal efficacy in increasing 5-HT and NE levels [92].
\nRegarding tolerability, the most frequently recorded adverse effects were nausea, constipation, and sweating, although a small proportion (3–6%) of patients recorded increased blood pressure and heart rate [93]. We have not found any data regarding its use in chronic pain patients.
\nA particular category of drugs includes SRIs with double mechanism: 5-HT reuptake inhibition and interaction with 5-HT receptors. Animal studies have suggested that these receptors are included in the descending pain inhibitory systems [94, 95], and their activation is involved in reducing the acute nociceptive and neuropathic pain [96].
\nTrazodone (Desyrel™, Oleptro™) is the first non-tricyclic antidepressant approved for the treatment of MDD (1981), and it is also used to treat anxiety, alcohol dependence, insomnia, and chronic pain (off-label). It was developed for the treatment of “mental pain,” which was recognized to occur in depression [97]. It acts as a SRI, antagonist of 5-HTA2 receptor, and a partial agonist for 5-HTA1 receptors. Secondary acts as an antagonist to α1-adrenergic receptors and lacks any effect on cholinergic receptors. The drug shows a 65% oral bioavailability, 90% plasma protein binding capacity, and is metabolized in the liver (via CYP3A4) to an active metabolite—mCPP. The main excretion route is renal, and the biological half-time is 7 h. Side effects are not only shared with the other antidepressants but also list dry mouth, orthostatic hypotension, cardiac arrhythmias, and priapism.
\nTrazodone showed some efficacy in several chronic pain conditions represented in Table 6, but future studies are needed.
\nStudy | \nChronic pain condition | \nDose | \nNumber of patients | \nComparator | \nEfficiency | \n
---|---|---|---|---|---|
Wilson [103] | \nDiabetic neuropathy | \n50–100 mg | \n31 | \n— | \nEffective | \n
Ventafridda et al. [104] | \nDeafferentation pain | \n— | \n45 | \nAmitriptyline | \nEqual efficacy | \n
Goodkin et al. [105] | \nChronic low back pain | \n201 mg (average) | \n42 | \nPlacebo | \nSimilar effect | \n
Morillas-Arques et al. [106] | \nFibromyalgia | \n50–300 mg | \n66 | \n— | \nEffective | \n
Calandre et al. [107] | \nFibromyalgia | \n50–300 mg trazodone + 75–450 mg pregabalin | \n41 | \n— | \nPregabalin enhanced the favorable effects of trazodone | \n
Davidoff et al. [108] | \nDysesthetic pain following spinal cord injury | \n150 mg | \n18 | \nplacebo | \nSimilar effect | \n
Battistella et al. [109] | \nMigraine (pediatric 7–18 years) | \n1 mg/kg | \n40 | \nplacebo | \nEffective | \n
Frank et al. [110] | \nRheumatoid arthritis | \n1.5 mg/kg | \n47 | \n— | \nNo effect | \n
Trials for trazodone in chronic pain management.
Nefazodone (Serzone™) is related to trazodone but with fewer side effects. Doses of 300–600 mg are indicated for the treatment of MDD, panic disorders, and aggressive behavior. It acts as an antagonist of 5-HTA2 and 5-HTC2 receptors and serotonin, norepinephrine, and dopamine reuptake inhibitor. Its effects on the mentioned receptors enhance neurotransmission by an increased binding on the 5-HTA1 receptors. Nefazodone shows an affinity for α1 and less for β-adrenoreceptors and does not interact with muscarinic cholinergic receptors. It has low bioavailability; it is metabolized in the liver (CYP3A4) and has four metabolites (mCPP active). Nefazodone has a biological half-time between 2 and 4 h and is excreted in urine. Frequent side effects are dry mouth, dizziness, and sleepiness, and rare, severe liver damage [98].
\nMurine studies yielded the capacity of nefazodone to potentiate opioid analgesia by acting through μ1 and μ2 receptors without affecting mortality [99]. Other results indicated that rats treated with nefazodone have shown an increased expression of μ-opioid receptors in the area of the central nervous system related to pain perception and modulation [100].
\nEven if it shows an excellent clinical profile, at this time we found only a two-center open-label study on the efficacy of nefazodone on preventing chronic daily headache. The study included 52 patients who received nefazodone between 100 and 450 mg (300 mg median) for 12 weeks. The results showed significantly lower incidence and intensity of daily headache and a good tolerance for nefazodone [101].
\nVilazodone (Viibryd™) approved by FDA (2011) for the treatment of MDD is a partial agonist to the 5-HTA1 receptor, GABA agonist, and SRI. Currently is presumed that it increases serotoninergic neurotransmission and it shows fast onset and good effect at daily doses between 10 and 40 mg. Vilazodone has 72% bioavailability when it is taken with food, is metabolized in the liver (via CYP3A4), and it did not possess active metabolites. It is excreted in urine and feces and has a biological half-time of 25 h [102]. Side effects include nausea, vomiting, diarrhea, and insomnia (>5%). Sexual adverse reactions and low influence on weight-gain were reported [103]. Even if it presumed that vilazodone should add value in the treatment of patients with the depression-pain syndrome, there are not yet available data on its efficacy in pain states.
\nSSRIs seem to be effective in most chronic pain conditions, and they are well tolerated [41]. The efficacy of SSRIs might be comparable to TADs and SNRIs, but their tolerability and safety are superior [30]. For some chronic pain conditions, valuable, while for others their utility is limited:
For migraine, SSRIs are not better than placebo for reducing the number of attacks, and results of studies on migraine are conflicting [24, 111].
Patients with chronic tension-type headache seem to benefit from SSRIs [24].
There are conflicting results regarding the use of SSRIs for pelvic pain.
Non-cardiac chest pain might benefit from SSRIs.
Low back pain does not seem to respond well to SSRIs.
The effects of SSRIs on fibromyalgia are uncertain [112].
Diabetic neuropathy looks to improve from SSRIs treatment.
Post stroke central pain might improve with fluvoxamine.
Evidences support that antidepressants are useful for the treatment of irritable bowel syndrome [113].
There is no evidence from randomized controlled trials to recommend antidepressants to treat chronic non-cancer pain in children and adolescents [114] or adults.
Even though several clinical trials were published, the results remain inconclusive. That happens because the sample sizes are quite modest rendering the studies slightly underpowered. Primary outcomes are variable: self-reported pain scores, effect on pain symptoms observed by the physician, complex pain questionnaires, and effects on quality of life and functionality. Current drug classes available for chronic pain treatment include anti-inflammatory drugs, opioids, gabapentinoids along with interventional or surgical management, and physical activity. Heterogeneity of the chronic pain syndromes, many currently available drugs and treatment modalities, and drug-drug and drug-interventional management associations should be considered when designing future larger scale trials.
\nIn conclusion, compared to all other antidepressants in the management of chronic pain, for SSRIs, the data are still inconclusive, and studies are fewer in number. For depression, SSRIs are considered first-line agents due to a favorable side-effect profile and good tolerability. However, they have not yet entered first-line use for neuropathic pain conditions [12]. Probably, it would be advisable to restrict their use for those patients failing to respond to other medications or who do not tolerate side effects.
\nFrom SNRIs category, in particular duloxetine is already a first-line treatment for DPN and other chronic pain syndromes (fibromyalgia, musculoskeletal pain, and osteoarthritis), showing good results and an acceptable safety profile. It also showed favorable effects on chronic postoperative pain and life quality with the perioperative administration in surgery with a high incidence of chronic pain (spine, breast). Venlafaxine is a drug of choice for the treatment of fibromyalgia. Milnacipran proved antiallodynic and antihyperalgesic effects and might show further positive results in chronic pain management; well-designed trials are still required.
\nSRIs seem to play their role through the spinal modulation pain pathways being less involved in reducing nociception, and that is probably why their effects are more evident in patients with chronic pain states.
\nNothing to declare.
We pride ourselves to live and function by our beliefs that scientific progress is fueled by collaboration, that the playing field for scientific research should be leveled globally, combined in a democratic environment with the use of innovative technologies, and made available to anyone at the click of a mouse.
\\n\\nThe high standard of our science publishing has not gone unnoticed. We proudly subscribe to the Budapest Initiative and are members of many Open Access publishing organizations:
\\n\\nWe are members of relevant trade associations and our books are regularly submitted to and indexed by major scientific databases including Web of Science’s Book Citation Index.
\\n\\n\\n"},{"imagePath":"/media/thumbnail/780x430/112","type":"mediaComponent","mediaType":"image","mimeType":null,"caption":"","originalUrl":"/media/thumbnail/600x600/112","alignment":"center"},{"type":"htmlEditorComponent","content":"
Within a year of our founding, we started working with NASA, and the list of globally-recognized funders with whom we are honored to work with keeps expanding. The research of IntechOpen’s Academic Editors and Fellows, and our Open Access book publishing, has been financed through funders such as:
\\n\\nIntechOpen’s Academic Editors and Authors are members of our growing scientific community focused on quality, peer-reviewed research and expeditious spreading of knowledge. Our community comprises of senior members of the international academic and scientific community across all fields of science, whose merits include Nobel Laureates and the world's top 1% most cited authors.
\\n"}]'},components:[{type:"htmlEditorComponent",content:'We pride ourselves to live and function by our beliefs that scientific progress is fueled by collaboration, that the playing field for scientific research should be leveled globally, combined in a democratic environment with the use of innovative technologies, and made available to anyone at the click of a mouse.
\n\nThe high standard of our science publishing has not gone unnoticed. We proudly subscribe to the Budapest Initiative and are members of many Open Access publishing organizations:
\n\nWe are members of relevant trade associations and our books are regularly submitted to and indexed by major scientific databases including Web of Science’s Book Citation Index.
\n\n\n'},{imagePath:"/media/thumbnail/780x430/112",type:"mediaComponent",mediaType:"image",mimeType:null,caption:"",originalUrl:"/media/thumbnail/600x600/112",alignment:"center"},{type:"htmlEditorComponent",content:"
Within a year of our founding, we started working with NASA, and the list of globally-recognized funders with whom we are honored to work with keeps expanding. The research of IntechOpen’s Academic Editors and Fellows, and our Open Access book publishing, has been financed through funders such as:
\n\nIntechOpen’s Academic Editors and Authors are members of our growing scientific community focused on quality, peer-reviewed research and expeditious spreading of knowledge. Our community comprises of senior members of the international academic and scientific community across all fields of science, whose merits include Nobel Laureates and the world's top 1% most cited authors.
\n"}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[],filtersByRegion:[],offset:0,limit:12,total:null},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{hasNoEditors:"1",sort:"dateEndThirdStepPublish",topicId:"22,16"},books:[{type:"book",id:"7543",title:"Physical Therapy Effectiveness",subtitle:null,isOpenForSubmission:!0,hash:"93377540da309c7e9bf2a7dc286b6c77",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/7543.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7852",title:"Pathologic Angiogenesis",subtitle:null,isOpenForSubmission:!0,hash:"2e2e79aa033b6f1c096eb1fb9be03d1c",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/7852.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7845",title:"Platelet Aggregation Inhibitors",subtitle:null,isOpenForSubmission:!0,hash:"dd19b595b164bfa1a5d25bab59506203",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/7845.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7844",title:"Management of Dysphagia",subtitle:null,isOpenForSubmission:!0,hash:"b780818606f915bd0c5adc01c5ba6ae3",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/7844.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7851",title:"Hypoactive Sexual Desire Disorder",subtitle:null,isOpenForSubmission:!0,hash:"665f7c67bc3facc09f09e0b70afea5ca",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/7851.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7924",title:"Schizophrenia-associated Genes",subtitle:null,isOpenForSubmission:!0,hash:"ce708b3755681e60aa7d979c4c5c3cb2",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/7924.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7919",title:"NK Cells and Cancer",subtitle:null,isOpenForSubmission:!0,hash:"c80f9dd27c01d74fbd8c0cfaf3faf1fb",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/7919.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7920",title:"Pathophysiology of Septic Shock",subtitle:null,isOpenForSubmission:!0,hash:"02964c19541acf8b3b00388809b47440",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/7920.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8224",title:"Growth Hormone Deficiency",subtitle:null,isOpenForSubmission:!0,hash:"bec48e63beeeaf2a5aba48c6b476ecb8",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/8224.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8672",title:"Health Care Informatics and Robotics - Foundations, Principles, Trends, Applications and Perspectives",subtitle:null,isOpenForSubmission:!0,hash:"87d87d0284e422a9e16da613b5393cee",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/8672.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8737",title:"Rabies Infections in Humans",subtitle:null,isOpenForSubmission:!0,hash:"a8719834076ff54fc0bcb8d767766b7c",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/8737.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8733",title:"Side-effects of Penicilin",subtitle:null,isOpenForSubmission:!0,hash:"bcb5e7b509de6ba98f7ed4eeff208df0",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/8733.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:64},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:77},{group:"topic",caption:"Business, Management and Economics",value:7,count:10},{group:"topic",caption:"Chemistry",value:8,count:33},{group:"topic",caption:"Computer and Information Science",value:9,count:34},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:23},{group:"topic",caption:"Engineering",value:11,count:69},{group:"topic",caption:"Environmental Sciences",value:12,count:15},{group:"topic",caption:"Immunology and Microbiology",value:13,count:14},{group:"topic",caption:"Materials Science",value:14,count:24},{group:"topic",caption:"Mathematics",value:15,count:20},{group:"topic",caption:"Medicine",value:16,count:185},{group:"topic",caption:"Nanotechnology and Nanomaterials",value:17,count:2},{group:"topic",caption:"Neuroscience",value:18,count:13},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:20},{group:"topic",caption:"Physics",value:20,count:35},{group:"topic",caption:"Psychology",value:21,count:4},{group:"topic",caption:"Robotics",value:22,count:1},{group:"topic",caption:"Social Sciences",value:23,count:24},{group:"topic",caption:"Technology",value:24,count:10},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:3}],offset:12,limit:12,total:186},popularBooks:{featuredBooks:[],offset:0,limit:12,total:null},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"7452",title:"Microbiology of Urinary Tract Infections",subtitle:"Microbial Agents and Predisposing Factors",isOpenForSubmission:!1,hash:"e99363f3cb1fe89c406f4934a23033d0",slug:"microbiology-of-urinary-tract-infections-microbial-agents-and-predisposing-factors",bookSignature:"Payam Behzadi",coverURL:"https://cdn.intechopen.com/books/images_new/7452.jpg",editors:[{id:"45803",title:"Ph.D.",name:"Payam",middleName:null,surname:"Behzadi",slug:"payam-behzadi",fullName:"Payam Behzadi"}],productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7437",title:"Nanomedicines",subtitle:null,isOpenForSubmission:!1,hash:"0e1f5f6258f074c533976c4f4d248568",slug:"nanomedicines",bookSignature:"Muhammad Akhyar Farrukh",coverURL:"https://cdn.intechopen.com/books/images_new/7437.jpg",editors:[{id:"63182",title:"Dr.",name:"Muhammad Akhyar",middleName:null,surname:"Farrukh",slug:"muhammad-akhyar-farrukh",fullName:"Muhammad Akhyar Farrukh"}],productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7519",title:"Sol-Gel Method",subtitle:"Design and Synthesis of New Materials with Interesting Physical, Chemical and Biological Properties",isOpenForSubmission:!1,hash:"cf094d22ebcb3083749e5f96e47f7769",slug:"sol-gel-method-design-and-synthesis-of-new-materials-with-interesting-physical-chemical-and-biological-properties",bookSignature:"Guadalupe Valverde Aguilar",coverURL:"https://cdn.intechopen.com/books/images_new/7519.jpg",editors:[{id:"186652",title:"Dr.",name:"Guadalupe",middleName:null,surname:"Valverde Aguilar",slug:"guadalupe-valverde-aguilar",fullName:"Guadalupe Valverde Aguilar"}],productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"2160",title:"MATLAB",subtitle:"A Fundamental Tool for Scientific Computing and Engineering Applications - Volume 1",isOpenForSubmission:!1,hash:"dd9c658341fbd264ed4f8d9e6aa8ca29",slug:"matlab-a-fundamental-tool-for-scientific-computing-and-engineering-applications-volume-1",bookSignature:"Vasilios N. Katsikis",coverURL:"https://cdn.intechopen.com/books/images_new/2160.jpg",editors:[{id:"12289",title:"Prof.",name:"Vasilios",middleName:"N.",surname:"Katsikis",slug:"vasilios-katsikis",fullName:"Vasilios Katsikis"}],productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3568",title:"Recent Advances in Plant in vitro Culture",subtitle:null,isOpenForSubmission:!1,hash:"830bbb601742c85a3fb0eeafe1454c43",slug:"recent-advances-in-plant-in-vitro-culture",bookSignature:"Annarita Leva and Laura M. R. Rinaldi",coverURL:"https://cdn.intechopen.com/books/images_new/3568.jpg",editors:[{id:"142145",title:"Dr.",name:"Annarita",middleName:null,surname:"Leva",slug:"annarita-leva",fullName:"Annarita Leva"}],productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"1770",title:"Gel Electrophoresis",subtitle:"Principles and Basics",isOpenForSubmission:!1,hash:"279701f6c802cf02deef45103e0611ff",slug:"gel-electrophoresis-principles-and-basics",bookSignature:"Sameh Magdeldin",coverURL:"https://cdn.intechopen.com/books/images_new/1770.jpg",editors:[{id:"123648",title:"Dr.",name:"Sameh",middleName:null,surname:"Magdeldin",slug:"sameh-magdeldin",fullName:"Sameh Magdeldin"}],productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"6679",title:"Serotonin",subtitle:null,isOpenForSubmission:!1,hash:"9c833c86546ec9d3c38fb24a1072dbd0",slug:"serotonin",bookSignature:"Ying Qu",coverURL:"https://cdn.intechopen.com/books/images_new/6679.jpg",editors:[{id:"94028",title:"Dr.",name:"Ying",middleName:null,surname:"Qu",slug:"ying-qu",fullName:"Ying Qu"}],productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"6856",title:"Gold Nanoparticles",subtitle:"Reaching New Heights",isOpenForSubmission:!1,hash:"23e172496e46e18712a901308d074cfb",slug:"gold-nanoparticles-reaching-new-heights",bookSignature:"Mohammed Rahman and Abdullah Mohammed Asiri",coverURL:"https://cdn.intechopen.com/books/images_new/6856.jpg",editors:[{id:"24438",title:"Prof.",name:"Mohammed",middleName:"Muzibur",surname:"Rahman",slug:"mohammed-rahman",fullName:"Mohammed Rahman"}],productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"632",title:"Wide Spectra of Quality Control",subtitle:null,isOpenForSubmission:!1,hash:"9f7ce64f86daee44a8c5604e8924de1c",slug:"wide-spectra-of-quality-control",bookSignature:"Isin Akyar",coverURL:"https://cdn.intechopen.com/books/images_new/632.jpg",editors:[{id:"36323",title:"Dr.",name:"Isin",middleName:null,surname:"Akyar",slug:"isin-akyar",fullName:"Isin Akyar"}],productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3037",title:"MATLAB",subtitle:"A Fundamental Tool for Scientific Computing and Engineering Applications - Volume 3",isOpenForSubmission:!1,hash:"1de63ac4f2c398a1304a7c08ee883655",slug:"matlab-a-fundamental-tool-for-scientific-computing-and-engineering-applications-volume-3",bookSignature:"Vasilios N. Katsikis",coverURL:"https://cdn.intechopen.com/books/images_new/3037.jpg",editors:[{id:"12289",title:"Prof.",name:"Vasilios",middleName:"N.",surname:"Katsikis",slug:"vasilios-katsikis",fullName:"Vasilios Katsikis"}],productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"6151",title:"Noninvasive Ventilation in Medicine",subtitle:"Recent Updates",isOpenForSubmission:!1,hash:"77e2fc8d909ac2458e0087490ea02a6d",slug:"noninvasive-ventilation-in-medicine-recent-updates",bookSignature:"Mayank Vats",coverURL:"https://cdn.intechopen.com/books/images_new/6151.jpg",editedByType:"Edited by",editors:[{id:"148941",title:"Dr.",name:"Mayank",middleName:"Gyan",surname:"Vats",slug:"mayank-vats",fullName:"Mayank Vats"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7437",title:"Nanomedicines",subtitle:null,isOpenForSubmission:!1,hash:"0e1f5f6258f074c533976c4f4d248568",slug:"nanomedicines",bookSignature:"Muhammad Akhyar Farrukh",coverURL:"https://cdn.intechopen.com/books/images_new/7437.jpg",editedByType:"Edited by",editors:[{id:"63182",title:"Dr.",name:"Muhammad Akhyar",middleName:null,surname:"Farrukh",slug:"muhammad-akhyar-farrukh",fullName:"Muhammad Akhyar Farrukh"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6679",title:"Serotonin",subtitle:null,isOpenForSubmission:!1,hash:"9c833c86546ec9d3c38fb24a1072dbd0",slug:"serotonin",bookSignature:"Ying Qu",coverURL:"https://cdn.intechopen.com/books/images_new/6679.jpg",editedByType:"Edited by",editors:[{id:"94028",title:"Dr.",name:"Ying",middleName:null,surname:"Qu",slug:"ying-qu",fullName:"Ying Qu"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7452",title:"Microbiology of Urinary Tract Infections",subtitle:"Microbial Agents and Predisposing Factors",isOpenForSubmission:!1,hash:"e99363f3cb1fe89c406f4934a23033d0",slug:"microbiology-of-urinary-tract-infections-microbial-agents-and-predisposing-factors",bookSignature:"Payam Behzadi",coverURL:"https://cdn.intechopen.com/books/images_new/7452.jpg",editedByType:"Edited by",editors:[{id:"45803",title:"Ph.D.",name:"Payam",middleName:null,surname:"Behzadi",slug:"payam-behzadi",fullName:"Payam Behzadi"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7215",title:"Recent Developments in Photovoltaic Materials and Devices",subtitle:null,isOpenForSubmission:!1,hash:"2f824828c2212e79b75fa65b194c5007",slug:"recent-developments-in-photovoltaic-materials-and-devices",bookSignature:"Natarajan Prabaharan, Marc A. Rosen and Pietro Elia Campana",coverURL:"https://cdn.intechopen.com/books/images_new/7215.jpg",editedByType:"Edited by",editors:[{id:"199317",title:"Dr.",name:"Natarajan",middleName:null,surname:"Prabaharan",slug:"natarajan-prabaharan",fullName:"Natarajan Prabaharan"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7485",title:"Applied Modern Control",subtitle:null,isOpenForSubmission:!1,hash:"c7a7be73f7232e08867ed81bdf9850c6",slug:"applied-modern-control",bookSignature:"Le Anh Tuan",coverURL:"https://cdn.intechopen.com/books/images_new/7485.jpg",editedByType:"Edited by",editors:[{id:"180550",title:"Dr.",name:"Le",middleName:null,surname:"Anh Tuan",slug:"le-anh-tuan",fullName:"Le Anh Tuan"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7488",title:"Analytical Pyrolysis",subtitle:null,isOpenForSubmission:!1,hash:"30a667792c3a70b53d30fb6e9e1e7b4d",slug:"analytical-pyrolysis",bookSignature:"Peter Kusch",coverURL:"https://cdn.intechopen.com/books/images_new/7488.jpg",editedByType:"Edited by",editors:[{id:"254714",title:"Dr.",name:"Peter",middleName:null,surname:"Kusch",slug:"peter-kusch",fullName:"Peter Kusch"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7242",title:"Engineered Fabrics",subtitle:null,isOpenForSubmission:!1,hash:"757cc326df7bcca72c8c850d9f4f71d1",slug:"engineered-fabrics",bookSignature:"Mukesh Kumar Singh",coverURL:"https://cdn.intechopen.com/books/images_new/7242.jpg",editedByType:"Edited by",editors:[{id:"36895",title:"Dr.",name:"Mukesh Kumar",middleName:null,surname:"Singh",slug:"mukesh-kumar-singh",fullName:"Mukesh Kumar Singh"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7245",title:"Challenging Issues on Paranasal Sinuses",subtitle:null,isOpenForSubmission:!1,hash:"67a331ebb2dd2b8f73228fa4daa7382f",slug:"challenging-issues-on-paranasal-sinuses",bookSignature:"Tang-Chuan Wang",coverURL:"https://cdn.intechopen.com/books/images_new/7245.jpg",editedByType:"Edited by",editors:[{id:"201262",title:"Dr.",name:"Tang-Chuan",middleName:null,surname:"Wang",slug:"tang-chuan-wang",fullName:"Tang-Chuan Wang"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7519",title:"Sol-Gel Method",subtitle:"Design and Synthesis of New Materials with Interesting Physical, Chemical and Biological Properties",isOpenForSubmission:!1,hash:"cf094d22ebcb3083749e5f96e47f7769",slug:"sol-gel-method-design-and-synthesis-of-new-materials-with-interesting-physical-chemical-and-biological-properties",bookSignature:"Guadalupe Valverde Aguilar",coverURL:"https://cdn.intechopen.com/books/images_new/7519.jpg",editedByType:"Edited by",editors:[{id:"186652",title:"Dr.",name:"Guadalupe",middleName:null,surname:"Valverde Aguilar",slug:"guadalupe-valverde-aguilar",fullName:"Guadalupe Valverde Aguilar"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"966",title:"Dynamical Systems Theory",slug:"dynamical-systems-theory",parent:{title:"Applied Mathematics",slug:"applied-mathematics"},numberOfBooks:5,numberOfAuthorsAndEditors:117,numberOfWosCitations:14,numberOfCrossrefCitations:29,numberOfDimensionsCitations:53},booksByTopicFilter:{topicSlug:"dynamical-systems-theory",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"6651",title:"Nonlinear Systems",subtitle:"Modeling, Estimation, and Stability",isOpenForSubmission:!1,hash:"085cfe19a4bd48a9e8034b2e5cc17172",slug:"nonlinear-systems-modeling-estimation-and-stability",bookSignature:"Mahmut Reyhanoglu",coverURL:"https://cdn.intechopen.com/books/images_new/6651.jpg",editedByType:"Edited by",editors:[{id:"15068",title:"Dr.",name:"Mahmut",middleName:null,surname:"Reyhanoglu",slug:"mahmut-reyhanoglu",fullName:"Mahmut Reyhanoglu"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6216",title:"Complexity in Biological and Physical Systems",subtitle:"Bifurcations, Solitons and Fractals",isOpenForSubmission:!1,hash:"c511a26efc1b9c0638c8f9244240cb93",slug:"complexity-in-biological-and-physical-systems-bifurcations-solitons-and-fractals",bookSignature:"Ricardo López-Ruiz",coverURL:"https://cdn.intechopen.com/books/images_new/6216.jpg",editedByType:"Edited by",editors:[{id:"9849",title:"Prof.",name:"Ricardo",middleName:null,surname:"Lopez-Ruiz",slug:"ricardo-lopez-ruiz",fullName:"Ricardo Lopez-Ruiz"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5804",title:"Fractal Analysis",subtitle:"Applications in Physics, Engineering and Technology",isOpenForSubmission:!1,hash:"a3d42b4b44ba9d7d72f0e91442da7b4b",slug:"fractal-analysis-applications-in-physics-engineering-and-technology",bookSignature:"Fernando Brambila",coverURL:"https://cdn.intechopen.com/books/images_new/5804.jpg",editedByType:"Edited by",editors:[{id:"60921",title:"Dr.",name:"Fernando",middleName:null,surname:"Brambila",slug:"fernando-brambila",fullName:"Fernando Brambila"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5513",title:"Dynamical Systems",subtitle:"Analytical and Computational Techniques",isOpenForSubmission:!1,hash:"9ba4129f30ef1b92fd4b7ae193781183",slug:"dynamical-systems-analytical-and-computational-techniques",bookSignature:"Mahmut Reyhanoglu",coverURL:"https://cdn.intechopen.com/books/images_new/5513.jpg",editedByType:"Edited by",editors:[{id:"15068",title:"Dr.",name:"Mahmut",middleName:null,surname:"Reyhanoglu",slug:"mahmut-reyhanoglu",fullName:"Mahmut Reyhanoglu"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2508",title:"Nonlinearity, Bifurcation and Chaos",subtitle:"Theory and Applications",isOpenForSubmission:!1,hash:"cce4e2af0e23321e7072373518985b63",slug:"nonlinearity-bifurcation-and-chaos-theory-and-applications",bookSignature:"Jan Awrejcewicz and Peter Hagedorn",coverURL:"https://cdn.intechopen.com/books/images_new/2508.jpg",editedByType:"Edited by",editors:[{id:"68338",title:"Prof.",name:"Jan",middleName:null,surname:"Awrejcewicz",slug:"jan-awrejcewicz",fullName:"Jan Awrejcewicz"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:5,mostCitedChapters:[{id:"40430",doi:"10.5772/50403",title:"Mathematical Modelling and Numerical Investigations on the Coanda Effect",slug:"mathematical-modelling-and-numerical-investigations-on-the-coanda-effect",totalDownloads:3760,totalCrossrefCites:10,totalDimensionsCites:17,book:{slug:"nonlinearity-bifurcation-and-chaos-theory-and-applications",title:"Nonlinearity, Bifurcation and Chaos",fullTitle:"Nonlinearity, Bifurcation and Chaos - Theory and Applications"},signatures:"A. Dumitrache, F. Frunzulica and T.C. Ionescu",authors:[{id:"151443",title:"Dr.",name:"Dumitrache",middleName:null,surname:"Alexandru",slug:"dumitrache-alexandru",fullName:"Dumitrache Alexandru"},{id:"151449",title:"Dr.",name:"Frunzulica",middleName:null,surname:"Florin",slug:"frunzulica-florin",fullName:"Frunzulica Florin"},{id:"151451",title:"Dr.",name:"Ionescu",middleName:null,surname:"Tudor",slug:"ionescu-tudor",fullName:"Ionescu Tudor"}]},{id:"53920",doi:"10.5772/67216",title:"Integral-Equation Formulations of Plasmonic Problems in the Visible Spectrum and Beyond",slug:"integral-equation-formulations-of-plasmonic-problems-in-the-visible-spectrum-and-beyond",totalDownloads:797,totalCrossrefCites:7,totalDimensionsCites:10,book:{slug:"dynamical-systems-analytical-and-computational-techniques",title:"Dynamical Systems",fullTitle:"Dynamical Systems - Analytical and Computational Techniques"},signatures:"Abdulkerim Çekinmez, Barişcan Karaosmanoğlu and Özgür Ergül",authors:[{id:"195936",title:"Associate Prof.",name:"Ozgur",middleName:null,surname:"Ergul",slug:"ozgur-ergul",fullName:"Ozgur Ergul"},{id:"203161",title:"Mr.",name:"Abdulkerim",middleName:null,surname:"Cekinmez",slug:"abdulkerim-cekinmez",fullName:"Abdulkerim Cekinmez"},{id:"203162",title:"MSc.",name:"Bariscan",middleName:null,surname:"Karaosmanoglu",slug:"bariscan-karaosmanoglu",fullName:"Bariscan Karaosmanoglu"}]},{id:"40435",doi:"10.5772/48168",title:"Dynamics of a Pendulum of Variable Length and Similar Problems",slug:"dynamics-of-a-pendulum-of-variable-length-and-similar-problems",totalDownloads:1488,totalCrossrefCites:0,totalDimensionsCites:5,book:{slug:"nonlinearity-bifurcation-and-chaos-theory-and-applications",title:"Nonlinearity, Bifurcation and Chaos",fullTitle:"Nonlinearity, Bifurcation and Chaos - Theory and Applications"},signatures:"A. O. Belyakov and A. P. Seyranian",authors:[{id:"139917",title:"Dr.",name:"Alexander",middleName:null,surname:"Seyranian",slug:"alexander-seyranian",fullName:"Alexander Seyranian"},{id:"140154",title:"Dr.",name:"Anton",middleName:null,surname:"Belyakov",slug:"anton-belyakov",fullName:"Anton Belyakov"}]}],mostDownloadedChaptersLast30Days:[{id:"54366",title:"Solution of Differential Equations with Applications to Engineering Problems",slug:"solution-of-differential-equations-with-applications-to-engineering-problems",totalDownloads:1898,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"dynamical-systems-analytical-and-computational-techniques",title:"Dynamical Systems",fullTitle:"Dynamical Systems - Analytical and Computational Techniques"},signatures:"Cheng Yung Ming",authors:[{id:"191017",title:"Dr.",name:"Cheng",middleName:null,surname:"Y.M.",slug:"cheng-y.m.",fullName:"Cheng Y.M."}]},{id:"54899",title:"Fractals in Antennas and Metamaterials Applications",slug:"fractals-in-antennas-and-metamaterials-applications",totalDownloads:826,totalCrossrefCites:0,totalDimensionsCites:1,book:{slug:"fractal-analysis-applications-in-physics-engineering-and-technology",title:"Fractal Analysis",fullTitle:"Fractal Analysis - Applications in Physics, Engineering and Technology"},signatures:"Wojciech Jan Krzysztofik",authors:[{id:"198646",title:"Prof.",name:"Wojciech",middleName:"Jan",surname:"Krzysztofik",slug:"wojciech-krzysztofik",fullName:"Wojciech Krzysztofik"}]},{id:"55048",title:"Application of Fractal Dimension in Industry Practice",slug:"application-of-fractal-dimension-in-industry-practice",totalDownloads:671,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"fractal-analysis-applications-in-physics-engineering-and-technology",title:"Fractal Analysis",fullTitle:"Fractal Analysis - Applications in Physics, Engineering and Technology"},signatures:"Vlastimil Hotař",authors:[{id:"199387",title:"Ph.D.",name:"Vlastimil",middleName:null,surname:"Hotař",slug:"vlastimil-hotar",fullName:"Vlastimil Hotař"}]},{id:"55238",title:"On the Indicatrixes of Waves Scattering from the Random Fractal Anisotropic Surface",slug:"on-the-indicatrixes-of-waves-scattering-from-the-random-fractal-anisotropic-surface",totalDownloads:515,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"fractal-analysis-applications-in-physics-engineering-and-technology",title:"Fractal Analysis",fullTitle:"Fractal Analysis - Applications in Physics, Engineering and Technology"},signatures:"Alexander A. Potapov",authors:[{id:"197044",title:"Prof.",name:"Alexander",middleName:null,surname:"Potapov",slug:"alexander-potapov",fullName:"Alexander Potapov"}]},{id:"55326",title:"Application of Fractional Calculus to Oil Industry",slug:"application-of-fractional-calculus-to-oil-industry",totalDownloads:657,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"fractal-analysis-applications-in-physics-engineering-and-technology",title:"Fractal Analysis",fullTitle:"Fractal Analysis - Applications in Physics, Engineering and Technology"},signatures:"Benito F. Martínez-Salgado, Rolando Rosas-Sampayo, Anthony\nTorres-Hernández and Carlos Fuentes",authors:[{id:"60920",title:"Dr.",name:"Carlos",middleName:null,surname:"Fuentes",slug:"carlos-fuentes",fullName:"Carlos Fuentes"},{id:"201272",title:"Prof.",name:"Rolando",middleName:null,surname:"Rosas-Sampayo",slug:"rolando-rosas-sampayo",fullName:"Rolando Rosas-Sampayo"},{id:"201279",title:"M.Sc.",name:"Benito Fernando",middleName:null,surname:"Martinez-Salgado",slug:"benito-fernando-martinez-salgado",fullName:"Benito Fernando Martinez-Salgado"},{id:"201282",title:"Prof.",name:"Anthony",middleName:null,surname:"Torres",slug:"anthony-torres",fullName:"Anthony Torres"}]},{id:"40430",title:"Mathematical Modelling and Numerical Investigations on the Coanda Effect",slug:"mathematical-modelling-and-numerical-investigations-on-the-coanda-effect",totalDownloads:3760,totalCrossrefCites:10,totalDimensionsCites:17,book:{slug:"nonlinearity-bifurcation-and-chaos-theory-and-applications",title:"Nonlinearity, Bifurcation and Chaos",fullTitle:"Nonlinearity, Bifurcation and Chaos - Theory and Applications"},signatures:"A. Dumitrache, F. Frunzulica and T.C. Ionescu",authors:[{id:"151443",title:"Dr.",name:"Dumitrache",middleName:null,surname:"Alexandru",slug:"dumitrache-alexandru",fullName:"Dumitrache Alexandru"},{id:"151449",title:"Dr.",name:"Frunzulica",middleName:null,surname:"Florin",slug:"frunzulica-florin",fullName:"Frunzulica Florin"},{id:"151451",title:"Dr.",name:"Ionescu",middleName:null,surname:"Tudor",slug:"ionescu-tudor",fullName:"Ionescu Tudor"}]},{id:"55169",title:"Factors Affecting Accuracy and Precision in Measuring Material Surfaces",slug:"factors-affecting-accuracy-and-precision-in-measuring-material-surfaces",totalDownloads:672,totalCrossrefCites:0,totalDimensionsCites:1,book:{slug:"fractal-analysis-applications-in-physics-engineering-and-technology",title:"Fractal Analysis",fullTitle:"Fractal Analysis - Applications in Physics, Engineering and Technology"},signatures:"Jason A. Griggs",authors:[{id:"197787",title:"Prof.",name:"Jason",middleName:null,surname:"Griggs",slug:"jason-griggs",fullName:"Jason Griggs"}]},{id:"54851",title:"Applications of Radial Basis Function Schemes to Fractional Partial Differential Equations",slug:"applications-of-radial-basis-function-schemes-to-fractional-partial-differential-equations",totalDownloads:711,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"fractal-analysis-applications-in-physics-engineering-and-technology",title:"Fractal Analysis",fullTitle:"Fractal Analysis - Applications in Physics, Engineering and Technology"},signatures:"Carlos Alberto Torres Martínez and Carlos Fuentes",authors:[{id:"201199",title:"Ph.D. Student",name:"Carlos",middleName:null,surname:"Torres",slug:"carlos-torres",fullName:"Carlos Torres"}]},{id:"54730",title:"Fractal Geometry and Porosity",slug:"fractal-geometry-and-porosity",totalDownloads:738,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"fractal-analysis-applications-in-physics-engineering-and-technology",title:"Fractal Analysis",fullTitle:"Fractal Analysis - Applications in Physics, Engineering and Technology"},signatures:"Oluranti Agboola, Maurice Steven Onyango, Patricia Popoola and\nOpeyemi Alice Oyewo",authors:[{id:"93463",title:"Prof.",name:"Maurice",middleName:null,surname:"Onyango",slug:"maurice-onyango",fullName:"Maurice Onyango"},{id:"169258",title:"Dr.",name:"Patricia",middleName:null,surname:"Popoola",slug:"patricia-popoola",fullName:"Patricia Popoola"},{id:"199472",title:"Dr.",name:"Oluranti",middleName:null,surname:"Agboola",slug:"oluranti-agboola",fullName:"Oluranti Agboola"},{id:"202204",title:"Dr.",name:"Opeyemi Alice",middleName:"Alice",surname:"Oyewo",slug:"opeyemi-alice-oyewo",fullName:"Opeyemi Alice Oyewo"}]},{id:"54621",title:"Specific Emitter Identification Based on Fractal Features",slug:"specific-emitter-identification-based-on-fractal-features",totalDownloads:762,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"fractal-analysis-applications-in-physics-engineering-and-technology",title:"Fractal Analysis",fullTitle:"Fractal Analysis - Applications in Physics, Engineering and Technology"},signatures:"Janusz Dudczyk",authors:[{id:"197688",title:"Prof.",name:"Janusz",middleName:null,surname:"Dudczyk",slug:"janusz-dudczyk",fullName:"Janusz Dudczyk"}]}],onlineFirstChaptersFilter:{topicSlug:"dynamical-systems-theory",limit:3,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},privacyPolicy:{},sponsorshipBooks:{sponsorshipBooks:[],offset:0,limit:8,total:null},humansInSpaceProgram:{},route:{name:"chapter.detail",path:"/books/polymerase-chain-reaction/study-of-mycobacterium-tuberculosis-by-molecular-methods-in-northeast-mexico",hash:"",query:{},params:{book:"polymerase-chain-reaction",chapter:"study-of-mycobacterium-tuberculosis-by-molecular-methods-in-northeast-mexico"},fullPath:"/books/polymerase-chain-reaction/study-of-mycobacterium-tuberculosis-by-molecular-methods-in-northeast-mexico",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()